Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
TECENTRIQ HYBREZA is a fixed-combination drug product containing atezolizumab and hyaluronidase (human recombinant).
TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) injection for subcutaneous use is a sterile, preservative-free, clear and slightly opalescent, and colorless to slightly yellow solution in single-dose vials. Each 15 mL single-dose vial contains 1,875 mg of atezolizumab, 30,000 units of hyaluronidase, histidine (46.5 mg), methionine (22.4 mg), polysorbate 20 (9 mg), sucrose (1,232 mg), and water for injection, adjusted to pH 5.8 with acetic acid.
TECENTRIQ HYBREZA, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
TECENTRIQ HYBREZA, in combination with bevacizumab, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
TECENTRIQ HYBREZA, in combination with cobimetinib and vemurafenib, is indicated for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test [see DOSAGE AND ADMINISTRATION].
TECENTRIQ HYBREZA, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic alveolar soft part sarcoma (ASPS).
Select adult patients with:
Information on FDA-approved tests for the determination of PD-L1 expression in metastatic NSCLC or for detection of BRAF V600 mutations in melanoma is available at: https://www.fda.gov/CompanionDiagnostics.
The recommended dosage of TECENTRIQ HYBREZA is one 15 mL injection (containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase, referred to as TECENTRIQ HYBREZA) administered subcutaneously in the thigh over approximately 7 minutes every 3 weeks.
Administration instructions for TECENTRIQ HYBREZA as monotherapy and in combination with other therapeutic agents are presented in Table 1. For the recommended dosage of each therapeutic agent administered in combination with TECENTRIQ HYBREZA refer to the product’s respective Prescribing Information.
Table 1: TECENTRIQ HYBREZA Administration Instructions and Duration of Therapy
| Indication | Administration Instructions for TECENTRIQ HYBREZA | Duration of Therapy |
| Adjuvant Treatment of Non-Small Cell Lung Cancer | Administer TECENTRIQ HYBREZA as monotherapy | Up to one year, unless there is disease recurrence or unacceptable toxicity |
| Metastatic Non-Small Cell Lung Cancer | Until disease progression or unacceptable toxicity | |
| Non-Small Cell Lung Cancer | Administer TECENTRIQ HYBREZA prior to chemotherapy and bevacizumab when given on the same day. | Until disease progression or unacceptable toxicity |
| Small Cell Lung Cancer | Administer TECENTRIQ HYBREZA prior to chemotherapy when given on the same day. | |
| Hepatocellular Carcinoma | Administer TECENTRIQ HYBREZA prior to bevacizumab when given on the same day. Bevacizumab is administered intravenously at 15 mg/kg every 3 weeks. | |
| Melanoma | Prior to initiating TECENTRIQ HYBREZA, patients should receive the following 28-day treatment cycle of cobimetinib and vemurafenib:
|
|
| Alveolar Soft Part Sarcoma | Administer TECENTRIQ HYBREZA as monotherapy | Until disease progression or unacceptable toxicity |
No dose reduction for TECENTRIQ HYBREZA is recommended. In general, withhold TECENTRIQ HYBREZA for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue TECENTRIQ HYBREZA for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce the daily corticosteroid dosage to 10 mg or less of prednisone or equivalent corticosteroid dosage within 12 weeks of initiating corticosteroids.
Dosage modifications for TECENTRIQ HYBREZA for adverse reactions that require management different from these general guidelines are summarized in Table 2.
Table 2: Recommended Dosage Modifications for Adverse Reactions
| Adverse Reaction | Severitya | Dosage Modification |
| Immune-Mediated Adverse Reactions [see WARNINGS AND PRECAUTIONS] | ||
| Pneumonitis | Grade 2 | Withholdb |
| Grades 3 or 4 | Permanently discontinue | |
| Colitis | Grades 2 or 3 | Withholdb |
| Grade 4 | Permanently discontinue | |
| Hepatitis with no tumor involvement of the liver | AST or ALT increases to more than 3 and up to 8 times ULN or Total bilirubin increases to more than 1.5 and up to 3 times ULN |
Withholdb |
| AST or ALT increases to more than 8 times ULN or Total bilirubin increases to more than 3 times ULN |
Permanently discontinue | |
| Hepatitis with tumor involvement of the liverc | Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN or Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN |
Withholdb |
| AST or ALT increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN |
Permanently discontinue | |
| Endocrinopathies | Grades 3 or 4 | Withhold until clinically stable or permanently discontinue depending on severity |
| Nephritis with Renal Dysfunction | Grades 2 or 3 increased blood creatinine | Withholdb |
| Grade 4 increased blood creatinine | Permanently discontinue | |
| Exfoliative Dermatologic Conditions | Suspected SJS, TEN, or DRESS | Withhold |
| Confirmed SJS, TEN, or DRESS | Permanently discontinue | |
| Myocarditis or pericarditis | Grades 2, 3, or 4 | Permanently discontinue |
| Neurological Toxicities | Grade 2 | Withholdb |
| Grades 3 or 4 | Permanently discontinue | |
| Other Adverse Reactions | ||
| Infusion-Related Reactions [see WARNINGS AND PRECAUTIONS] | Grades 1 or 2 | Pause or slow the rate of injection Premedication with antipyretic and antihistamines may be considered for subsequent doses. |
| Grades 3 or 4 | Permanently discontinue | |
| a Based on Common Terminology Criteria for Adverse Events (CTCAE), version 5 b Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids c If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue TECENTRIQ HYBREZA based on recommendations for hepatitis with no liver involvement ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit normal, DRESS = Drug Rash with Eosinophilia and Systemic Symptoms, SJS = Stevens Johnson syndrome, TEN = toxic epidermal necrolysis |
||
TECENTRIQ HYBREZA does not contain any antimicrobial preservative. If the TECENTRIQ HYBREZA dose is not administered immediately, refer to “Storage Instructions” [see DOSAGE AND ADMINISTRATION].
Injection: 1,875 mg atezolizumab and 30,000 units hyaluronidase per 15 mL (125 mg and 2,000 units per mL) clear to slightly opalescent, and colorless to slightly yellow solution in a single-dose vial.
TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) injection for subcutaneous use is a sterile, preservative-free, clear to slightly opalescent, and colorless to slightly yellow solution. It is supplied in a carton containing:
1,875 mg and 30,000 units/15 mL (125 mg and 2,000 units/mL) in a single-dose vial (NDC 50242-933-01).
Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake.
Manufactured by: Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990. Revised: Sep 2024
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of TECENTRIQ HYBREZA was evaluated in IMscin001, open-label, multi-center, international, randomized trial for patients with locally advanced or metastatic NSCLC who have not been exposed to cancer immunotherapy and who have had disease progression on prior platinum-based therapy [see Clinical Studies]. Patients with previously treated metastatic non-small cell lung cancer (NSCLC) either received TECENTRIQ HYBREZA (containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase) administered subcutaneously into the thigh over approximately 7 minutes every 3 weeks or intravenous atezolizumab every 3 weeks until disease progression or unacceptable toxicity. Among 247 patients who received TECENTRIQ HYBREZA, 32% were exposed for 6 months or longer and 8% were exposed for greater than one year.
The median age was 64 years (range: 27 to 85); 69% male; 67% White, 22% Asian, 0.8% Black or African American; 74% were non-Hispanic or Latino; 26% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 74% had an ECOG PS of 1; and 70% of patients were current or previous smokers.
Serious adverse reactions occurred in 19% of patients who received TECENTRIQ HYBREZA. Serious adverse reactions (> 1%) included pneumonia, myocardial infarction, and pleural effusion. Fatal adverse reactions occurred in 6% of patients who received TECENTRIQ HYBREZA, including pneumonia (2.4%), myocardial infarction (1.2%), head injury (0.4%), ischemic stroke (0.4%), pleural effusion (0.4%), pulmonary embolism (0.4%), respiratory tract infection (0.4%), sepsis (0.4%), and toxic epidermal necrolysis (0.4%).
Permanent discontinuation of TECENTRIQ HYBREZA due to an adverse reaction occurred in 3.6% of patients. Adverse reactions which resulted in permanent discontinuation of TECENTRIQ HYBREZA in > 1% of patients included pneumonia (2%).
Dosage interruptions of TECENTRIQ HYBREZA due to an adverse reaction occurred in 32% of patients. Adverse reactions which required dosage interruption in > 1% of patients were COVID-19 (4.9%), increased aspartate aminotransferase (2.8%), increased alanine aminotransferase (2.4%), pneumonia (2.4%), anemia (1.6%), dyspnea (1.6%), fatigue (1.2%), and viral respiratory tract infection (1.2%). The most common adverse reactions of any grade (occurring in ≥ 10% of patients) were fatigue (19%), musculoskeletal pain (15%), cough (13%), dyspnea (12%), and decreased appetite (11%).
Tables 3 and 4 summarize adverse reactions and selected laboratory abnormalities, respectively in TECENTRIQ HYBREZA-treated patients in IMscin001.
Table 3: Adverse Reactions (≥ 10%) in Adult Patients with Locally Advanced or Metastatic NSCLC Who Received TECENTRIQ HYBREZA in IMscin001
| Adverse Reaction* | TECENTRIQ HYBREZA n = 247 |
Intravenous Atezolizumab n = 124 |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| General Disorder and Administration Site Conditions | ||||
| Fatigue1 | 19 | 0.8 | 18 | 0 |
| Musculoskeletal and Connective Tissue disorders | ||||
| Musculoskeletal Pain2 | 15 | 0.4 | 13 | 3.2 |
| Respiratory, Thoracic and Mediastinal | ||||
| Cough3 | 13 | 0 | 7 | 0 |
| Dyspnea4 | 12 | 1.2 | 15 | 1.6 |
| Metabolism and Nutrition Disorders | ||||
| Decreased appetite | 11 | 0 | 11 | 0 |
| * Graded per NCI CTCAE v5.0 1 Composite term includes fatigue, asthenia 2 Composite term includes back pain, myalgia, bone pain, musculoskeletal chest pain, neck pain, spinal pain, non-cardiac chest pain 3 Composite term includes cough, productive cough 4 Composite term includes dyspnea, dyspnea at rest, dyspnea exertional |
||||
Clinically relevant adverse reactions in < 10% of patients who received TECENTRIQ HYBREZA were local injection site reactions (4.5%) and pyrexia (1.2%).
Table 4: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Adult Patients with Advanced or Metastatic NSCLC Who Received TECENTRIQ HYBREZA in IMscin001
| Laboratory Abnormality1 | TECENTRIQ HYBREZA (n = 247) |
Intravenous Atezolizumab (n = 124) |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Hematology | ||||
| Decreased Hemoglobin | 67 | 6 | 63 | 5 |
| Decreased lymphocytes | 37 | 9 | 45 | 15 |
| Chemistry | ||||
| Decreased Sodium | 46 | 3.9 | 47 | 5 |
| Decreased Albumin | 34 | 2.2 | 27 | 0 |
| Increased Alkaline Phosphatase | 33 | 1.3 | 27 | 0 |
| Increased AST | 28 | 2.6 | 32 | 2.6 |
| Increased ALT | 28 | 2.6 | 23 | 1.7 |
| Decreased calcium | 22 | 2.6 | 23 | 0.9 |
| Increased calcium | 20 | 2.6 | 24 | 1.7 |
| Increased potassium | 21 | 1.7 | 22 | 1.7 |
| Increased INR | 20 | 2 | 23 | 0 |
| Increased Creatinine | 19 | 1.7 | 26 | 0.9 |
| Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: TECENTRIQ HYBREZA (48-233) and intravenous atezolizumab (19-117) 1 Graded per NCI CTCAE v5.0 |
||||
The safety of TECENTRIQ HYBREZA for its approved NSCLC indications [see INDICATIONS AND USAGE] has been established in adequate and well-controlled studies of intravenous atezolizumab for the:
Below is a description of adverse reactions of intravenous atezolizumab in these adequate and well-controlled NSCLC studies.
IMpower010
The safety of intravenous atezolizumab was evaluated in IMpower010, a multicenter, open-label, randomized trial for the adjuvant treatment of patients with stage IB (tumors ≥ 4 cm) -IIIA NSCLC who had complete tumor resection and received up to 4 cycles of cisplatin-based adjuvant chemotherapy. Patients received intravenous atezolizumab 1200 mg every 3 weeks (n = 495) for 1 year (16 cycles), unless disease progression or unacceptable toxicity occurred, or best supportive care [see Clinical Studies]. The median number of cycles received was 16 (range: 1, 16).
Fatal adverse reactions occurred in 1.8% of patients receiving intravenous atezolizumab; these included multiple organ dysfunction syndrome, pneumothorax, interstitial lung disease, arrhythmia, acute cardiac failure, myocarditis, cerebrovascular accident, death of unknown cause, and acute myeloid leukemia (1 patient each).
Serious adverse reactions occurred in 18% of patients receiving intravenous atezolizumab. The most frequent serious adverse reactions (> 1%) were pneumonia (1.8%), pneumonitis (1.6%), and pyrexia (1.2%).
Intravenous atezolizumab was discontinued due to adverse reactions in 18% of patients; the most common adverse reactions (≥ 1%) leading to intravenous atezolizumab discontinuation were pneumonitis (2.2%), hypothyroidism (1.6%), increased aspartate aminotranferase (1.4%), arthralgia (1.0%), and increased alanine aminotransferase (1.0%).
Adverse reactions leading to interruption of intravenous atezolizumab occurred in 29% of patients; the most common (> 1%) were rash (3.0%), hyperthyroidism (2.8%), hypothyroidism (1.6%), increased AST (1.6%), pyrexia (1.6%), increased ALT (1.4%), upper respiratory tract infection (1.4%), headache (1.2%), peripheral neuropathy (1.2%), and pneumonia (1.2%).
Tables 5 and 6 summarize adverse reactions and selected laboratory abnormalities in patients receiving intravenous atezolizumab in IMpower010.
Table 5: Adverse Reactions Occurring in ≥ 10% of Patients with Early-Stage NSCLC Receiving Intravenous Atezolizumab in IMpower010
| Adverse Reaction* | Intravenous Atezolizumab N = 495 |
Best Supportive Care N = 495 |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Skin and Subcutaneous Tissue | ||||
| Rash1 | 17 | 1.2 | 1.4 | 0 |
| Pruritus | 10 | 0 | 0.6 | 0 |
| Endocrine Disorders | ||||
| Hypothyroidism2 | 14 | 0 | 0.6 | 0 |
| Respiratory, Thoracic and Mediastinal | ||||
| Cough3 | 16 | 0 | 11 | 0 |
| General | ||||
| Pyrexia4 | 14 | 0.8 | 2.2 | 0.2 |
| Fatigue5 | 14 | 0.6 | 5 | 0.2 |
| Nervous System Disorders | ||||
| Peripheral neuropathy6 | 12 | 0.4 | 7 | 0.2 |
| Musculoskeletal and Connective Tissue | ||||
| Musculoskeletal pain7 | 14 | 0.8 | 9 | 0.2 |
| Arthralgia8 | 11 | 0.6 | 6 | 0 |
| * Graded per NCI CTCAE v4.0 1 Includes rash, dermatitis, genital rash, skin exfoliation, rash maculo-papular, rash erythematous, rash papular, lichen planus, eczema asteatotic, dermatitis exfoliative, palmar-plantar erythrodysaesthesia syndrome, dyshidrotic eczema, eczema, drug eruption, rash pruritic, toxic skin eruption, dermatitis acneiform 2 Includes hypothyroidism, autoimmune hypothyroidism, primary hypothyroidism, blood thyroid stimulating hormone increased 3 Productive cough, upper airway cough syndrome, cough 4 Includes pyrexia, body temperature increased, hyperthermia 5 Includes fatigue, asthenia 6 Includes paraesthesia, neuropathy peripheral, peripheral sensory neuropathy, hypoaesthesia, polyneuropathy, dysaesthesia, neuralgia, axonal neuropathy 7 Includes myalgia, bone pain, back pain, spinal pain, musculoskeletal chest pain, pain in extremity, neck pain, non-cardiac chest pain, musculoskeletal discomfort, musculoskeletal stiffness, musculoskeletal pain 8 Includes arthralgia, arthritis |
||||
Table 6: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients with Early-Stage NSCLC Receiving Intravenous Atezolizumab in IMpower010
| Laboratory Abnormality1 | Intravenous Atezolizumab2 | Best Supportive Care2 | ||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Chemistry | ||||
| Increased aspartate aminotransferase | 34 | 2.5 | 18 | 0 |
| Increased alanine aminotransferase | 30 | 3.3 | 19 | 0.4 |
| Hyperkalemia | 24 | 3.5 | 15 | 2.5 |
| Increased blood creatinine | 31 | 0.2 | 23 | 0.2 |
| 1 Graded per NCI CTCAE v4.0, except for increased creatinine which only includes patients with creatinine increase based on upper limit of normal definition for Grade 1 events (NCI CTCAE v5.0). 2 The denominators used to calculate the rate varied from 78–480 for BSC arm and 483 for intravenous atezolizumab are for all tests of interest based on the number of patients with a baseline value and at least one post-treatment value. |
||||
IMpower110
The safety of intravenous atezolizumab was evaluated in IMpower110, a multicenter, international, randomized, open-label study in 549 chemotherapy-naïve patients with stage IV NSCLC, including those with EGFR or ALK genomic tumor aberrations. Patients received intravenous atezolizumab 1200 mg every 3 weeks (n = 286) or platinum-based chemotherapy consisting of carboplatin or cisplatin with either pemetrexed or gemcitabine (n = 263) until disease progression or unacceptable toxicity [see Clinical Studies]. IMpower110 enrolled patients whose tumors express PD-L1 (PD-L1 stained ≥ 1% of tumor cells [TC] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 1% of the tumor area). The median duration of exposure to intravenous atezolizumab was 5.3 months (0 to 33 months).
Fatal adverse reactions occurred in 3.8% of patients receiving intravenous atezolizumab; these included death (reported as unexplained death and death of unknown cause), aspiration, chronic obstructive pulmonary disease, pulmonary embolism, acute myocardial infarction, cardiac arrest, mechanical ileus, sepsis, cerebral infarction, and device occlusion (1 patient each).
Serious adverse reactions occurred in 28% of patients receiving intravenous atezolizumab. The most frequent serious adverse reactions (> 2%) were pneumonia (2.8%), chronic obstructive pulmonary disease (2.1%) and pneumonitis (2.1%).
Intravenous atezolizumab was discontinued due to adverse reactions in 6% of patients; the most common adverse reactions (≥ 2 patients) leading to intravenous atezolizumab discontinuation were peripheral neuropathy and pneumonitis.
Adverse reactions leading to interruption of intravenous atezolizumab occurred in 26% of patients; the most common (> 1%) were ALT increased (2.1%), AST increased (2.1%), pneumonitis (2.1%), pyrexia (1.4%), pneumonia (1.4%) and upper respiratory tract infection (1.4%).
Tables 7 and 8 summarize adverse reactions and selected laboratory abnormalities in patients receiving intravenous atezolizumab in IMpower110.
Table 7: Adverse Reactions Occurring in ≥ 10% of Patients with NSCLC Receiving Intravenous Atezolizumab in IMpower110
| Adverse Reaction | Intravenous Atezolizumab N = 286 |
Platinum-Based Chemotherapy N = 263 |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Gastrointestinal | ||||
| Nausea | 14 | 0.3 | 34 | 1.9 |
| Constipation | 12 | 1.0 | 22 | 0.8 |
| Diarrhea | 11 | 0 | 12 | 0.8 |
| General | ||||
| Fatigue/Asthenia | 25 | 1.4 | 34 | 4.2 |
| Pyrexia | 14 | 0 | 9 | 0.4 |
| Metabolism and Nutrition | ||||
| Decreased appetite | 15 | 0.7 | 19 | 0 |
| Respiratory, Thoracic and Mediastinal | ||||
| Dyspnea | 14 | 0.7 | 10 | 0 |
| Cough | 12 | 0.3 | 10 | 0 |
| Graded per NCI CTCAE v4.0 | ||||
Table 8: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients Receiving Intravenous Atezolizumab in IMpower110
| Laboratory Abnormality | Intravenous Atezolizumab | Platinum-Based Chemotherapy | |||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | ||
| Hematology | |||||
| Anemia | 69 | 1.8 | 94 | 20 | |
| Lymphopenia | 47 | 9 | 59 | 17 | |
| Chemistry | |||||
| Hypoalbuminemia | 48 | 0.4 | 39 | 2 | |
| Increased alkaline phosphatase | 46 | 2.5 | 42 | 1.2 | |
| Hyponatremia | 44 | 9 | 36 | 7 | |
| Increased ALT | 38 | 3.2 | 32 | 0.8 | |
| Increased AST | 36 | 3.2 | 32 | 0.8 | |
| Hyperkalemia | 29 | 3.9 | 36 | 2.7 | |
| Hypocalcemia | 24 | 1.4 | 24 | 2.7 | |
| Increased blood creatinine | 24 | 0.7 | 33 | 1.5 | |
| Hypophosphatemia | 23 | 3.6 | 21 | 2 | |
| Each test incidence is based on the number of patients who had at least one on-study laboratory measurement available: intravenous atezolizumab (range: 278–281); platinum-based chemotherapy (range: 256–260). Graded per NCI CTCAE v4.0. Increased blood creatinine only includes patients with test results above the normal range. | |||||
IMpower150
The safety of intravenous atezolizumab with bevacizumab, paclitaxel and carboplatin was evaluated in IMpower150, a multicenter, international, randomized, open-label trial in which 393 chemotherapy-naïve patients with metastatic non-squamous NSCLC received intravenous atezolizumab 1200 mg with bevacizumab 15 mg/kg, paclitaxel 175 mg/m2 or 200 mg/m2, and carboplatin AUC 6 mg/mL/min intravenously every 3 weeks for a maximum of 4 or 6 cycles, followed by intravenous atezolizumab 1200 mg with bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity [see Clinical Studies]. The median duration of exposure to intravenous atezolizumab was 8.3 months in patients receiving intravenous atezolizumab with bevacizumab, paclitaxel, and carboplatin.
Fatal adverse reactions occurred in 6% of patients receiving intravenous atezolizumab; these included hemoptysis, febrile neutropenia, pulmonary embolism, pulmonary hemorrhage, death, cardiac arrest, cerebrovascular accident, pneumonia, aspiration pneumonia, chronic obstructive pulmonary disease, intracranial hemorrhage, intestinal angina, intestinal ischemia, intestinal obstruction and aortic dissection.
Serious adverse reactions occurred in 44%. The most frequent serious adverse reactions (> 2%) were febrile neutropenia, pneumonia, diarrhea, and hemoptysis.
Intravenous atezolizumab was discontinued due to adverse reactions in 15% of patients; the most common adverse reaction leading to discontinuation was pneumonitis (1.8%).
Adverse reactions leading to interruption of intravenous atezolizumab occurred in 48%; the most common (> 1%) were neutropenia, thrombocytopenia, fatigue/asthenia, diarrhea, hypothyroidism, anemia, pneumonia, pyrexia, hyperthyroidism, febrile neutropenia, increased ALT, dyspnea, dehydration and proteinuria.
Tables 9 and 10 summarize adverse reactions and laboratory abnormalities in patients receiving intravenous atezolizumab with bevacizumab, paclitaxel, and carboplatin in IMpower150.
Table 9: Adverse Reactions Occurring in ≥ 15% of Patients with NSCLC Receiving Intravenous Atezolizumab in IMpower150
| Adverse Reaction | Intravenous Atezolizumab with Bevacizumab, Paclitaxel, and Carboplatin N = 393 |
Bevacizumab, Paclitaxel and Carboplatin N = 394 |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Nervous System | ||||
| Neuropathy1 | 56 | 3 | 47 | 3 |
| Headache | 16 | 0.8 | 13 | 0 |
| General | ||||
| Fatigue/Asthenia | 50 | 6 | 46 | 6 |
| Pyrexia | 19 | 0.3 | 9 | 0.5 |
| Skin and Subcutaneous Tissue | ||||
| Alopecia | 48 | 0 | 46 | 0 |
| Rash2 | 23 | 2 | 10 | 0.3 |
| Musculoskeletal and Connective Tissue | ||||
| Myalgia/Pain3 | 42 | 3 | 34 | 2 |
| Arthralgia | 26 | 1 | 22 | 1 |
| Gastrointestinal | ||||
| Nausea | 39 | 4 | 32 | 2 |
| Diarrhea4 | 33 | 6 | 25 | 0.5 |
| Constipation | 30 | 0.3 | 23 | 0.3 |
| Vomiting | 19 | 2 | 18 | 1 |
| Metabolism and Nutrition | ||||
| Decreased appetite | 29 | 4 | 21 | 0.8 |
| Vascular | ||||
| Hypertension | 25 | 9 | 22 | 8 |
| Respiratory | ||||
| Cough | 20 | 0.8 | 19 | 0.3 |
| Epistaxis | 17 | 1 | 22 | 0.3 |
| Renal | ||||
| Proteinuria5 | 16 | 3 | 15 | 3 |
| Graded per NCI CTCAE v4.0 1 Includes neuropathy peripheral, peripheral sensory neuropathy, hypoesthesia, paresthesia, dysesthesia, polyneuropathy 2 Includes rash, rash maculo-papular, drug eruption, eczema, eczema asteatotic, dermatitis, contact dermatitis, rash erythematous, rash macular, pruritic rash, seborrheic dermatitis, dermatitis psoriasiform 3 Includes pain in extremity, musculoskeletal chest pain, musculoskeletal discomfort, neck pain, back pain, myalgia, and bone pain 4 Includes diarrhea, gastroenteritis, colitis, enterocolitis 5 Based on adverse reaction terms since laboratory data for proteinuria was not systematically collected |
||||
Table 10: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients with NSCLC Receiving Intravenous Atezolizumab in IMpower150
| Laboratory Abnormality | Intravenous Atezolizumab with Bevacizumab, Paclitaxel, and Carboplatin | Bevacizumab, Paclitaxel and Carboplatin | ||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Hematology | ||||
| Anemia | 83 | 10 | 83 | 9 |
| Neutropenia | 52 | 31 | 45 | 26 |
| Lymphopenia | 48 | 17 | 38 | 13 |
| Chemistry | ||||
| Hyperglycemia | 61 | 0 | 60 | 0 |
| Increased BUN | 52 | NA1 | 44 | NA1 |
| Hypomagnesemia | 42 | 2 | 36 | 1 |
| Hypoalbuminemia | 40 | 3 | 31 | 2 |
| Increased AST | 40 | 4 | 28 | 0.8 |
| Hyponatremia | 38 | 10 | 36 | 9 |
| Increased Alkaline Phosphatase | 37 | 2 | 32 | 1 |
| Increased ALT | 37 | 6 | 28 | 0.5 |
| Increased TSH | 30 | NA1 | 20 | NA1 |
| Hyperkalemia | 28 | 3 | 25 | 2 |
| Increased Creatinine | 28 | 1 | 19 | 2 |
| Hypocalcemia | 26 | 3 | 21 | 3 |
| Hypophosphatemia | 25 | 4 | 18 | 4 |
| Hypokalemia | 23 | 7 | 14 | 4 |
| Hyperphosphatemia | 25 | NA1 | 19 | NA1 |
| Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: Intravenous Atezolizumab with bevacizumab, paclitaxel, and carboplatin range: (337–380); bevacizumab, paclitaxel, and carboplatin (range: 337–382). Graded per NCI CTCAE v4.0 1 NA = Not applicable. NCI CTCAE does not provide a Grades 3–4 definition for these laboratory abnormalities |
||||
IMpower130
The safety of intravenous atezolizumab with paclitaxel protein-bound and carboplatin was evaluated in IMpower130, a multicenter, international, randomized, open-label trial in which 473 chemotherapy-naïve patients with metastatic non-squamous NSCLC received intravenous atezolizumab 1200 mg and carboplatin AUC 6 mg/mL/min intravenously on Day 1 and paclitaxel protein-bound 100 mg/m2 intravenously on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 or 6 cycles, followed by intravenous atezolizumab 1200 mg intravenously every 3 weeks until disease progression or unacceptable toxicity [see Clinical Studies]. Among patients receiving intravenous atezolizumab, 55% were exposed for 6 months or longer and 3.5% were exposed for greater than one year.
Fatal adverse reactions occurred in 5.3% of patients receiving intravenous atezolizumab; these included pneumonia (1.1%), pulmonary embolism (0.8%), myocardial infarction (0.6%), cardiac arrest (0.4%), pneumonitis (0.4%) and sepsis, septic shock, staphylococcal sepsis, aspiration, respiratory distress, cardiorespiratory arrest, ventricular tachycardia, death (not otherwise specified), and hepatic cirrhosis (0.2% each).
Serious adverse reactions occurred in 51% of patients receiving intravenous atezolizumab. The most frequent serious adverse reactions (≥ 2%) were pneumonia (6%), diarrhea (3%), lung infection (3%), pulmonary embolism (3%), chronic obstructive pulmonary disease exacerbation (2.5%), dyspnea (2.3%), and febrile neutropenia (1.9%).
Intravenous atezolizumab was discontinued due to adverse reactions in 13% of patients; the most common adverse reactions leading to discontinuation were pneumonia (0.8%), pulmonary embolism (0.8%), fatigue (0.6%), dyspnea (0.6%), pneumonitis (0.6%), neutropenia (0.4%), nausea (0.4%), renal failure (0.4%), cardiac arrest (0.4%), and septic shock (0.4%).
Adverse reactions leading to interruption of intravenous atezolizumab occurred in 62% of patients; the most common (> 1%) were neutropenia, thrombocytopenia, anemia, diarrhea, fatigue/asthenia, pneumonia, dyspnea, pneumonitis, pyrexia, nausea, acute kidney injury, vomiting, pulmonary embolism, arthralgia, infusion-related reaction, abdominal pain, chronic obstructive pulmonary disease exacerbation, dehydration, and hypokalemia.
Tables 11 and 12 summarize adverse reactions and laboratory abnormalities in patients receiving intravenous atezolizumab with paclitaxel protein-bound and carboplatin in IMpower130.
Table 11: Adverse Reactions Occurring in ≥ 20% of Patients with NSCLC Receiving Intravenous Atezolizumab in IMpower130
| Adverse Reaction | Intravenous Atezolizumab with Paclitaxel Protein-Bound and Carboplatin N = 473 |
Paclitaxel Protein-Bound and Carboplatin N = 232 |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| General | ||||
| Fatigue/Asthenia | 61 | 11 | 60 | 8 |
| Gastrointestinal | ||||
| Nausea | 50 | 3.4 | 46 | 2.2 |
| Diarrhea1 | 43 | 6 | 32 | 6 |
| Constipation | 36 | 1.1 | 31 | 0 |
| Vomiting | 27 | 2.7 | 19 | 2.2 |
| Musculoskeletal and Connective Tissue | ||||
| Myalgia/Pain2 | 38 | 3 | 22 | 0.4 |
| Nervous System | ||||
| Neuropathy3 | 33 | 2.5 | 28 | 2.2 |
| Respiratory, Thoracic and Mediastinal | ||||
| Dyspnea4 | 32 | 4.9 | 25 | 1.3 |
| Cough | 27 | 0.6 | 17 | 0 |
| Skin and Subcutaneous Tissue | ||||
| Alopecia | 32 | 0 | 27 | 0 |
| Rash5 | 20 | 0.6 | 11 | 0.9 |
| Metabolism and Nutrition | ||||
| Decreased appetite | 30 | 2.1 | 26 | 2.2 |
| Graded per NCI CTCAE v4.0 1 Includes diarrhea, colitis, and gastroenteritis 2 Includes back pain, pain in extremity, myalgia, musculoskeletal chest pain, bone pain, neck pain and musculoskeletal discomfort 3 Includes neuropathy peripheral, peripheral sensory neuropathy, hypoesthesia, paresthesia, dysesthesia, polyneuropathy 4 Includes dyspnea, dyspnea exertional and wheezing 5 Includes rash, rash maculo-papular, eczema, rash pruritic, rash erythematous, dermatitis, dermatitis contact, drug eruption, seborrheic dermatitis and rash macular |
||||
Table 12: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients Receiving Intravenous Atezolizumab in IMpower130
| Laboratory Abnormality | Intravenous Atezolizumab with Paclitaxel Protein-Bound and Carboplatin N = 473 |
Paclitaxel Protein-Bound and Carboplatin N = 232 |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Hematology | ||||
| Anemia | 92 | 33 | 87 | 25 |
| Neutropenia | 75 | 50 | 67 | 39 |
| Thrombocytopenia | 73 | 19 | 59 | 13 |
| Lymphopenia | 71 | 23 | 61 | 16 |
| Chemistry | ||||
| Hyperglycemia | 75 | 8 | 66 | 8 |
| Hypomagnesemia | 50 | 3.4 | 42 | 3.2 |
| Hyponatremia | 37 | 9 | 28 | 7 |
| Hypoalbuminemia | 35 | 1.3 | 31 | 0 |
| Increased ALT | 31 | 2.8 | 24 | 3.9 |
| Hypocalcemia | 31 | 2.6 | 27 | 1.8 |
| Hypophosphatemia | 29 | 6 | 20 | 3.2 |
| Increased AST | 28 | 2.2 | 24 | 1.8 |
| Increased TSH | 26 | NA1 | 5 | NA1 |
| Hypokalemia | 26 | 6 | 24 | 4.4 |
| Increased Alkaline Phosphatase | 25 | 2.6 | 22 | 1.3 |
| Increased Blood Creatinine | 23 | 2.8 | 16 | 0.4 |
| Hyperphosphatemia | 21 | NA1 | 13 | NA1 |
| Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous atezolizumab with paclitaxel protein-bound and carboplatin (range: 423–467); paclitaxel protein-bound and carboplatin (range: 218–229). Graded per NCI CTCAE v4.0. 1 NA = Not applicable. NCI CTCAE does not provide a Grades 3–4 definition for these laboratory abnormalities |
||||
OAK
The safety of intravenous atezolizumab was evaluated in OAK, a multicenter, international, randomized, open-label trial in patients with metastatic NSCLC who progressed during or following a platinum-containing regimen, regardless of PD-L1 expression [see Clinical Studies]. A total of 609 patients received intravenous atezolizumab 1200 mg intravenously every 3 weeks until unacceptable toxicity, radiographic progression, or clinical progression or docetaxel (n = 578) 75 mg/m2 intravenously every 3 weeks until unacceptable toxicity or disease progression. The study excluded patients with active or prior autoimmune disease or with medical conditions that required systemic corticosteroids. The median duration of exposure was 3.4 months (0 to 26 months) in intravenous atezolizumab-treated patients and 2.1 months (0 to 23 months) in docetaxel-treated patients.
The study population characteristics were: median age of 63 years (25 to 85 years), 46% age 65 years or older, 62% male, 71% White, 20% Asian, 68% former smoker, 16% current smoker, and 63% had ECOG performance status of 1.
Fatal adverse reactions occurred in 1.6% of patients; these included pneumonia, sepsis, septic shock, dyspnea, pulmonary hemorrhage, sudden death, myocardial ischemia or renal failure.
Serious adverse reactions occurred in 33.5% of patients. The most frequent serious adverse reactions (> 1%) were pneumonia, sepsis, dyspnea, pleural effusion, pulmonary embolism, pyrexia and respiratory tract infection.
Intravenous atezolizumab was discontinued due to adverse reactions in 8% of patients. The most common adverse reactions leading to intravenous atezolizumab discontinuation were fatigue, infections and dyspnea. Adverse reactions leading to interruption of intravenous atezolizumab occurred in 25% of patients; the most common (> 1%) were pneumonia, liver function test abnormality, dyspnea, fatigue, pyrexia, and back pain.
Tables 13 and 14 summarize adverse reactions and laboratory abnormalities, respectively, in OAK.
Table 13: Adverse Reactions Occurring in ≥ 10% of Patients with NSCLC Receiving Intravenous Atezolizumab in OAK
| Adverse Reaction | Intravenous Atezolizumab N = 609 |
Docetaxel N = 578 |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| General | ||||
| Fatigue/Asthenia1 | 44 | 4 | 53 | 6 |
| Pyrexia | 18 | < 1 | 13 | < 1 |
| Respiratory | ||||
| Cough2 | 26 | < 1 | 21 | < 1 |
| Dyspnea | 22 | 2.8 | 21 | 2.6 |
| Metabolism and Nutrition | ||||
| Decreased appetite | 23 | < 1 | 24 | 1.6 |
| Musculoskeletal | ||||
| Myalgia/Pain3 | 20 | 1.3 | 20 | < 1 |
| Arthralgia | 12 | 0.5 | 10 | 0.2 |
| Gastrointestinal | ||||
| Nausea | 18 | < 1 | 23 | < 1 |
| Constipation | 18 | < 1 | 14 | < 1 |
| Diarrhea | 16 | < 1 | 24 | 2 |
| Skin | ||||
| Rash4 | 12 | < 1 | 10 | 0 |
| Graded per NCI CTCAE v4.0 1 Includes fatigue and asthenia 2 Includes cough and exertional cough 3 Includes musculoskeletal pain, musculoskeletal stiffness, musculoskeletal chest pain, myalgia 4 Includes rash, erythematous rash, generalized rash, maculopapular rash, papular rash, pruritic rash, pustular rash, pemphigoid |
||||
Table 14: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients with NSCLC Receiving Intravenous Atezolizumab in OAK
| Laboratory Abnormality | Intravenous Atezolizumab | Docetaxel | ||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Hematology | ||||
| Anemia | 67 | 3 | 82 | 7 |
| Lymphocytopenia | 49 | 14 | 60 | 21 |
| Chemistry | ||||
| Hypoalbuminemia | 48 | 4 | 50 | 3 |
| Hyponatremia | 42 | 7 | 31 | 6 |
| Increased Alkaline Phosphatase | 39 | 2 | 25 | 1 |
| Increased AST | 31 | 3 | 16 | 0.5 |
| Increased ALT | 27 | 3 | 14 | 0.5 |
| Hypophosphatemia | 27 | 5 | 23 | 4 |
| Hypomagnesemia | 26 | 1 | 21 | 1 |
| Increased Creatinine | 23 | 2 | 16 | 1 |
| Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous atezolizumab (range: 546-585) and docetaxel (range: 532-560). Graded according to NCI CTCAE version 4.0 | ||||
The safety of TECENTRIQ HYBREZA for its approved Small Cell Lung Cancer (SCLC) indication [see INDICATIONS AND USAGE] has been established in adequate and well-controlled studies of intravenous atezolizumab for SCLC (IMpower133 study).
IMpower133
The safety of intravenous atezolizumab with carboplatin and etoposide was evaluated in IMpower133, a randomized, multicenter, double-blind, placebo-controlled trial in which 198 patients with ES-SCLC received intravenous atezolizumab 1200 mg and carboplatin AUC 5 mg/mL/min on Day 1 and etoposide 100 mg/m2 intravenously on Days 1, 2 and 3 of each 21-day cycle for a maximum of 4 cycles, followed by intravenous atezolizumab 1200 mg every 3 weeks until disease progression or unacceptable toxicity [see Clinical Studies]. Among 198 patients receiving intravenous atezolizumab, 32% were exposed for 6 months or longer and 12% were exposed for 12 months or longer.
Fatal adverse reactions occurred in 2% of patients receiving intravenous atezolizumab. These included pneumonia, respiratory failure, neutropenia, and death (1 patient each).
Serious adverse reactions occurred in 37% of patients receiving intravenous atezolizumab. Serious adverse reactions in > 2% were pneumonia (4.5%), neutropenia (3.5%), febrile neutropenia (2.5%), and thrombocytopenia (2.5%).
Intravenous atezolizumab was discontinued due to adverse reactions in 11% of patients. The most frequent adverse reaction requiring permanent discontinuation in > 2% of patients was infusion-related reactions (2.5%).
Adverse reactions leading to interruption of intravenous atezolizumab occurred in 59% of patients; the most common (> 1%) were neutropenia (22%), anemia (9%), leukopenia (7%), thrombocytopenia (5%), fatigue (4.0%), infusion-related reaction (3.5%), pneumonia (2.0%), febrile neutropenia (1.5%), increased ALT (1.5%), and nausea (1.5%).
Tables 15 and 16 summarize adverse reactions and laboratory abnormalities, respectively, in patients who received intravenous atezolizumab with carboplatin and etoposide in IMpower133.
Table 15: Adverse Reactions Occurring in ≥ 20% of Patients with SCLC Receiving Intravenous Atezolizumab in IMpower133
| Adverse Reaction | Intravenous Atezolizumab with Carboplatin and Etoposide N = 198 |
Placebo with Carboplatin and Etoposide N = 196 |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| General | ||||
| Fatigue/Asthenia | 39 | 5 | 33 | 3 |
| Gastrointestinal | ||||
| Nausea | 38 | 1 | 33 | 1 |
| Constipation | 26 | 1 | 30 | 1 |
| Vomiting | 20 | 2 | 17 | 3 |
| Skin and Subcutaneous Tissue | ||||
| Alopecia | 37 | 0 | 35 | 0 |
| Metabolism and Nutrition | ||||
| Decreased appetite | 27 | 1 | 18 | 0 |
| Graded per NCI CTCAE v4.0 | ||||
Table 16: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients with SCLC Receiving Intravenous Atezolizumab in IMpower133
| Laboratory Abnormality | Intravenous Atezolizumab with Carboplatin and Etoposide | Placebo with Carboplatin and Etoposide | ||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Hematology | ||||
| Anemia | 94 | 17 | 93 | 19 |
| Neutropenia | 73 | 45 | 76 | 48 |
| Thrombocytopenia | 58 | 20 | 53 | 17 |
| Lymphopenia | 46 | 14 | 38 | 11 |
| Chemistry | ||||
| Hyperglycemia | 67 | 10 | 65 | 8 |
| Increased Alkaline Phosphatase | 38 | 1 | 35 | 2 |
| Hyponatremia | 34 | 15 | 33 | 11 |
| Hypoalbuminemia | 32 | 1 | 30 | 0 |
| Decreased TSH2 | 28 | NA1 | 15 | NA1 |
| Hypomagnesemia | 31 | 5 | 35 | 6 |
| Hypocalcemia | 26 | 3 | 28 | 5 |
| Increased ALT | 26 | 3 | 31 | 1 |
| Increased AST | 22 | 1 | 21 | 2 |
| Increased Blood Creatinine | 22 | 4 | 15 | 1 |
| Hyperphosphatemia | 21 | NA1 | 23 | NA1 |
| Increased TSH2 | 21 | NA1 | 7 | NA1 |
| Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: Intravenous Atezolizumab (range: 181–193); Placebo (range: 181–196). Graded per NCI CTCAE v4.0 1 NA = Not applicable 2 TSH = thyroid-stimulating hormone. NCI CTCAE v4.0 does not include these laboratories. |
||||
The safety of TECENTRIQ HYBREZA for its approved indication hepatocellular carcinoma [see INDICATIONS AND USAGE] has been established in adequate and well-controlled studies of intravenous atezolizumab for hepatocellular carcinoma (IMbrave150 study).
IMbrave150
The safety of intravenous atezolizumab in combination with bevacizumab was evaluated in IMbrave150, a multicenter, international, randomized, open-label trial in patients with locally advanced or metastatic or unresectable hepatocellular carcinoma who have not received prior systemic treatment [see Clinical Studies]. Patients received 1,200 mg of intravenous atezolizumab intravenously followed by 15 mg/kg bevacizumab (n = 329) every 3 weeks, or 400 mg of sorafenib (n = 156) given orally twice daily, until disease progression or unacceptable toxicity. The median duration of exposure to intravenous atezolizumab was 7.4 months (range: 0–16 months) and to bevacizumab was 6.9 months (range: 0–16 months).
Fatal adverse reactions occurred in 4.6% of patients in the intravenous atezolizumab and bevacizumab arm. The most common adverse reactions leading to death were gastrointestinal and esophageal varices hemorrhage (1.2%) and infections (1.2%).
Serious adverse reactions occurred in 38% of patients in the intravenous atezolizumab and bevacizumab arm. The most frequent serious adverse reactions (≥ 2%) were gastrointestinal hemorrhage (7%), infections (6%), and pyrexia (2.1%).
Adverse reactions leading to discontinuation of intravenous atezolizumab occurred in 9% of patients in the intravenous atezolizumab and bevacizumab arm. The most common adverse reactions leading to intravenous atezolizumab discontinuation were hemorrhages (1.2%), including gastrointestinal, subarachnoid, and pulmonary hemorrhages; increased transaminases or bilirubin (1.2%); infusion-related reaction/cytokine release syndrome (0.9%); and autoimmune hepatitis (0.6%).
Adverse reactions leading to interruption of intravenous atezolizumab occurred in 41% of patients in the intravenous atezolizumab and bevacizumab arm; the most common (≥ 2%) were liver function laboratory abnormalities including increased transaminases, bilirubin, or alkaline phosphatase (8%); infections (6%); gastrointestinal hemorrhages (3.6%); thrombocytopenia/decreased platelet count (3.6%); hyperthyroidism (2.7%); and pyrexia (2.1%).
Immune-related adverse reactions requiring systemic corticosteroid therapy occurred in 12% of patients in the intravenous atezolizumab and bevacizumab arm.
Tables 17 and 18 summarize adverse reactions and laboratory abnormalities, respectively, in patients who received intravenous atezolizumab and bevacizumab in IMbrave150.
Table 17: Adverse Reactions Occurring in ≥ 10% of Patients with HCC Receiving Intravenous Atezolizumab in IMbrave150
| Adverse Reaction | Intravenous Atezolizumab in combination with Bevacizumab (n = 329) |
Sorafenib (n = 156) |
||
| All Grades2 (%) | Grades 3-42 (%) | All Grades2 (%) | Grades 3-42 (%) | |
| Vascular Disorders | ||||
| Hypertension | 30 | 15 | 24 | 12 |
| General Disorders and Administration Site Conditions | ||||
| Fatigue/Asthenia1 | 26 | 2 | 32 | 6 |
| Pyrexia | 18 | 0 | 10 | 0 |
| Renal and Urinary Disorders | ||||
| Proteinuria | 20 | 3 | 7 | 0.6 |
| Investigations | ||||
| Weight Decreased | 11 | 0 | 10 | 0 |
| Skin and Subcutaneous Tissue Disorders | ||||
| Pruritus | 19 | 0 | 10 | 0 |
| Rash | 12 | 0 | 17 | 2.6 |
| Gastrointestinal Disorders | ||||
| Diarrhea | 19 | 1.8 | 49 | 5 |
| Constipation | 13 | 0 | 14 | 0 |
| Abdominal Pain | 12 | 0 | 17 | 0 |
| Nausea | 12 | 0 | 16 | 0 |
| Vomiting | 10 | 0 | 8 | 0 |
| Metabolism and Nutrition Disorders | ||||
| Decreased Appetite | 18 | 1.2 | 24 | 3.8 |
| Respiratory, Thoracic and Mediastinal Disorders | ||||
| Cough | 12 | 0 | 10 | 0 |
| Epistaxis | 10 | 0 | 4.5 | 0 |
| Injury, Poisoning and Procedural Complications | ||||
| Infusion-Related Reaction | 11 | 2.4 | 0 | 0 |
| 1 Includes fatigue and asthenia 2 Graded per NCI CTCAE v4.0 |
||||
Table 18: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients with HCC Receiving Intravenous Atezolizumab in IMbrave150
| Laboratory Abnormality | Intravenous Atezolizumab in combination with Bevacizumab (n = 329) |
Sorafenib (n = 156) |
||
| All Grades1 (%) | Grades 3-41 (%) | All Grades1 (%) | Grades 3-41 (%) | |
| Chemistry | ||||
| Increased AST | 86 | 16 | 90 | 16 |
| Increased Alkaline Phosphatase | 70 | 4 | 76 | 4.6 |
| Increased ALT | 62 | 8 | 70 | 4.6 |
| Decreased Albumin | 60 | 1.5 | 54 | 0.7 |
| Decreased Sodium | 54 | 13 | 49 | 9 |
| Increased Glucose | 48 | 9 | 43 | 4.6 |
| Decreased Calcium | 30 | 0.3 | 35 | 1.3 |
| Decreased Phosphorus | 26 | 4.7 | 58 | 16 |
| Increased Potassium | 23 | 1.9 | 16 | 2 |
| Hypomagnesemia | 22 | 0 | 22 | 0 |
| Hematology | ||||
| Decreased Platelet | 68 | 7 | 63 | 4.6 |
| Decreased Lymphocytes | 62 | 13 | 58 | 11 |
| Decreased Hemoglobin | 58 | 3.1 | 62 | 3.9 |
| Increased Bilirubin | 57 | 8 | 59 | 14 |
| Decreased Leukocyte | 32 | 3.4 | 29 | 1.3 |
| Decreased Neutrophil | 23 | 2.3 | 16 | 1.1 |
| Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous atezolizumab plus bevacizumab (222-323) and sorafenib (90-153) 1 Graded per NCI CTCAE v4.0 |
||||
The safety of TECENTRIQ HYBREZA for its approved melanoma indication [see INDICATIONS AND USAGE] has been established in adequate and well-controlled studies of intravenous atezolizumab for melanoma (IMspire150 study).
IMspire150
The safety of intravenous atezolizumab, administered with cobimetinib and vemurafenib, was evaluated in IMspire150, a double-blind, randomized (1:1), placebo-controlled study conducted in patients with previously untreated BRAF V600 mutation-positive metastatic or unresectable melanoma [see Clinical Studies]. Patients received intravenous atezolizuamb with cobimetinib and vemurafenib (n = 230) or placebo with cobimetinib and vemurafenib (n = 281).
Among the 230 patients who received intravenous atezolizumab administered with cobimetinib and vemurafenib, the median duration of exposure to intravenous atezolizumab was 9.2 months (range: 0–30 months), to cobimetinib was 10.0 months (range: 1–31 months) and to vemurafenib was 9.8 months (range: 1–31 months).
Fatal adverse reactions occurred in 3% of patients in the intravenous atezolizumab plus cobimetinib and vemurafenib arm. Adverse reactions leading to death were hepatic failure, fulminant hepatitis, sepsis, septic shock, pneumonia, and cardiac arrest.
Serious adverse reactions occurred in 45% of patients in the intravenous atezolizumab plus cobimetinib and vemurafenib arm. The most frequent (≥ 2%) serious adverse reactions were hepatotoxicity (7%), pyrexia (6%), pneumonia (4.3%), malignant neoplasms (2.2%), and acute kidney injury (2.2%).
Adverse reactions leading to discontinuation of intravenous atezolizumab occurred in 21% of patients in the intravenous atezolizumab plus cobimetinib and vemurafenib arm. The most frequent (≥ 2%) adverse reactions leading to intravenous atezolizumab discontinuation were increased ALT (2.2%) and pneumonitis (2.6%).
Adverse reactions leading to interruption of intravenous atezolizumab occurred in 68% of patients in the intravenous atezolizumab plus cobimetinib and vemurafenib arm. The most frequent (≥ 2%) adverse reactions leading to intravenous atezolizuamb interruption were pyrexia (14%), increased ALT (13%), hyperthyroidism (10%), increased AST (10%), increased lipase (9%), increased amylase (7%), pneumonitis (5%), increased CPK (4.3%), diarrhea (3.5%), pneumonia (3.5%), asthenia (3%), rash (3%), influenza (3%), arthralgia (2.6%), fatigue (2.2%), dyspnea (2.2%), cough (2.2%), peripheral edema (2.2%), uveitis (2.2%), bronchitis (2.2%), hypothyroidism (2.2%), and respiratory tract infection (2.2%).
Tables 19 and 20 summarize the incidence of adverse reactions and laboratory abnormalities in IMspire150.
Table 19: Adverse Reactions Occurring in ≥ 10% of Patients on the Intravenous Atezolizumab plus Cobimetinib and Vemurafenib Arm or the Placebo plus Cobimetinib and Vemurafenib Arm and at a Higher Incidence (Between Arm Difference of ≥ 5% All Grades or ≥ 2% Grades 3-4 Intravenous Atezolizumb in IMspire150)
| Adverse Reaction | Intravenous Atezolizumab in combination with Cobimetinib and Vemurafenib (n=230) |
Placebo with Cobimetinib and Vemurafenib (n=281) |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Skin and Subcutaneous Tissue Disorders | ||||
| Rash1 | 75 | 27 | 72 | 23 |
| Pruritus | 26 | < 1 | 17 | < 1 |
| Photosensitivity reaction | 21 | < 1 | 25 | 3.2 |
| General Disorders and Administration Site Conditions | ||||
| Fatigue2 | 51 | 3 | 45 | 1.8 |
| Pyrexia3 | 49 | 1.7 | 35 | 2.1 |
| Edema4 | 26 | < 1 | 21 | 0 |
| Gastrointestinal Disorders | ||||
| Hepatotoxicity5 | 50 | 21 | 36 | 13 |
| Nausea | 30 | < 1 | 32 | 2.5 |
| Stomatitis6 | 23 | 1.3 | 15 | < 1 |
| Musculoskeletal and Connective Tissue Disorders | ||||
| Musculoskeletal pain7 | 62 | 4.3 | 48 | 3.2 |
| Endocrine Disorders | ||||
| Hypothyroidism8 | 22 | 0 | 10 | 0 |
| Hyperthyroidism | 18 | < 1 | 8 | 0 |
| Injury, Poisoning and Procedural Complications | ||||
| Infusion-related reaction9 | 10 | 2.6 | 8 | < 1 |
| Respiratory, Thoracic and Mediastinal Disorders | ||||
| Pneumonitis10 | 12 | 1.3 | 6 | < 1 |
| Vascular Disorders | ||||
| Hypertension11 | 17 | 10 | 18 | 7 |
| 1 Includes rash, rash maculo-papular, dermatitis acneiform, rash macular, rash erythematous, eczema, skin exfoliation, rash papular, rash pustular, palmar-plantar erythrodysaesthesia syndrome, dermatitis, dermatitis contact, erythema multiforme, rash pruritic, drug eruption, nodular rash, dermatitis allergic, exfoliative rash, dermatitis exfoliative generalised and rash morbilliform 2 Includes fatigue, asthenia and malaise 3 Includes pyrexia and hyperpyrexia 4 Includes edema peripheral, lymphoedema, oedema, face oedema, eyelid oedema, periorbital oedema, lip oedema and generalised oedema 5 Includes alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, transaminases increased, hepatitis, hepatic enzyme increased, hepatotoxicity, hypertransaminasaemia, bilirubin conjugated increased, hepatocellular injury, hyperbilirubinaemia, liver function test increased, hepatic failure, hepatitis fulminant and liver function test abnormal 6 Includes stomatitis, mucosal inflammation, aphthous ulcer, mouth ulceration, cheilitis and glossitis 7 Includes arthralgia, myalgia, pain in extremity, back pain, musculoskeletal pain, arthritis, neck pain, musculoskeletal chest pain, musculoskeletal stiffness, bone pain, spinal pain, immune-mediated arthritis, joint stiffness and non-cardiac chest pain 8 Includes hypothyroidism and blood thyroid stimulating hormone increased 9 Includes infusion related reaction and hypersensitivity 10 Includes pneumonitis and interstitial lung disease 11 Includes hypertension, blood pressure increased, hypertensive crisis |
||||
Clinically important adverse reactions in < 10% of patients who received intravenous atezolizumab plus cobimetinib and vemurafenib were:
Cardiac Disorders: Arrhythmias, ejection fraction decreased, electrocardiogram QT prolonged
Eye Disorders: Uveitis
Gastrointestinal disorders: Pancreatitis
Infections and infestations: Pneumonia, urinary tract infection
Metabolism and nutrition disorders: Hyperglycemia
Nervous system Disorders: Dizziness, dysgeusia, syncope
Respiratory, thoracic and mediastinal disorders: Dyspnea, oropharyngeal pain
Skin and Subcutaneous Tissue Disorders: Vitiligo
Table 20: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients Receiving Intravenous Atezolizumab Plus Cobimetinib and Vemurafenib Arm or the Placebo Plus Cobimetinib and Vemurafenib Arm and at a Higher Incidence (Between Arm Difference of ≥ 5% All Grades or ≥ 2% Grades 3–4) in IMspire150
| Laboratory Abnormality | Intravenous Atezolizumab in combination with Cobimetinib and Vemurafenib (n=230) |
Placebo with Cobimetinib and Vemurafenib (n=281) |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Hematology | ||||
| Decreased Lymphocytes | 80 | 24 | 72 | 17 |
| Decreased Hemoglobin | 77 | 2.6 | 72 | 2.2 |
| Decreased Platelet | 34 | 1.3 | 24 | 0.4 |
| Decreased Neutrophils | 26 | 2.2 | 19 | 1.5 |
| Chemistry | ||||
| Increased Creatine Kinase | 88 | 22 | 81 | 18 |
| Increased AST | 80 | 13 | 68 | 6 |
| Increased ALT | 79 | 18 | 62 | 12 |
| Increased Triacylglycerol Lipase | 75 | 46 | 62 | 35 |
| Increased Alkaline Phosphatase | 73 | 6 | 63 | 2.9 |
| Decreased Phosphorus | 67 | 22 | 64 | 14 |
| Increased Amylase | 51 | 13 | 45 | 13 |
| Increased Blood Urea Nitrogen | 47 | NA1 | 37 | NA1 |
| Decreased Albumin | 43 | 0.9 | 34 | 1.5 |
| Increased Bilirubin | 42 | 3.1 | 33 | 0.7 |
| Decreased Calcium | 41 | 1.3 | 28 | 0 |
| Decreased Sodium | 40 | 5 | 34 | 7 |
| Decreased Thyroid-Stimulating Hormone | 38 | NA1 | 23 | NA1 |
| Increased Thyroid-Stimulating Hormone2 | 37 | NA1 | 33 | NA1 |
| Decreased Potassium | 36 | 5 | 22 | 4.3 |
| Increased Triiodothyronine | 33 | NA1 | 18 | NA1 |
| Increased Free Thyroxine | 32 | NA1 | 21 | NA1 |
| Decreased Total Triiodothyronine | 32 | NA1 | 8 | NA1 |
| Increased Potassium | 29 | 1.3 | 19 | 1.4 |
| Decreased Triiodothyronine | 27 | NA1 | 21 | NA1 |
| Increased Sodium | 20 | 0 | 13 | 0.4 |
| Graded per NCI CTCAE v4.0. Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous atezolizumab plus cobimetinib and vemurafenib (28-277), placebo plus cobimetinib and vemurafenib arm (25-230). 1 NA = Not applicable. NCI CTCAE v4.0 does not include these laboratories 2 Increased Thyroid Stimulating Hormone has a difference < 5% (All Grades) between arms and is included for clinical completeness |
||||
The safety of TECENTRIQ HYBREZA for its approved alveolar soft part sarcoma (ASPS) indication [see INDICATIONS AND USAGE] has been established in adequate and well-controlled studies of intravenous atezolizumab for ASPS (ML39345 study).
ML39345 Study
The safety of intravenous atezolizumab was evaluated in 47 adult and 2 pediatric patients enrolled in Study ML39345 [see Clinical Studies]. Adult patients received intravenous atezolizumab 1200 mg every 3 weeks and pediatric patients received 15 mg/kg up to a maximum 1200 mg every 3 weeks until disease progression or unacceptable toxicity. The median duration of exposure to intravenous atezolizumab was 8.9 months (1 to 40 months).
Serious adverse reactions occurred in 41% of patients receiving intravenous atezolizumab. The most frequent serious adverse reactions (> 2%) were fatigue, pain in extremity, pulmonary hemorrhage, and pneumonia (4.1% each).
Dosage interruptions of intravenous atezolizumab due to an adverse reaction occurred in 35% of patients. The most common adverse reactions (≥ 3%) leading to dose interruptions were pneumonitis and pain in extremity (4.1% each).
Tables 21 and 22 summarize adverse reactions and laboratory abnormalities in Study ML39345.
Table 21: Adverse Reactions Occurring in ≥ 15% of Patients with ASPS Receiving Intravenous Atezolizumab in ML39345
| Adverse Reaction | Intravenous Atezolizumab N = 49 |
|
| All Grades (%) | Grades 3-4 (%) | |
| General disorders and administration site conditions | ||
| Fatigue | 55 | 2 |
| Pyrexia | 25 | 2 |
| Influenza like illness | 18 | 0 |
| Gastrointestinal disorders | ||
| Nausea | 43 | 0 |
| Vomiting | 37 | 0 |
| Constipation | 33 | 0 |
| Diarrhea | 27 | 2 |
| Abdominal pain1 | 25 | 0 |
| Metabolism and nutrition disorders | ||
| Decreased appetite | 22 | 2 |
| Respiratory, Thoracic and Mediastinal | ||
| Cough2 | 45 | 0 |
| Dyspnea | 33 | 0 |
| Rhinitis allergic | 16 | 0 |
| Musculoskeletal and connective tissue disorders | ||
| Musculoskeletal pain3 | 67 | 8 |
| Skin and subcutaneous tissue disorders | ||
| Rash4 | 47 | 2 |
| Nervous system disorders | ||
| Headache | 43 | 4 |
| Dizziness5 | 29 | 4 |
| Vascular disorders | ||
| Hypertension | 43 | 6 |
| Hemorrhage6 | 29 | 2 |
| Psychiatric disorders | ||
| Insomnia | 27 | 0 |
| Anxiety | 25 | 0 |
| Cardiac Disorders | ||
| Arrhythmia7 | 22 | 2 |
| Endocrine disorders | ||
| Hypothyroidism8 | 25 | 0 |
| Investigations | ||
| Weight decreased | 18 | 0 |
| Weight increased | 16 | 6 |
| Graded per NCI CTCAE v4.0 1 Includes abdominal pain and abdominal pain upper 2 Includes cough, upper-airway cough syndrome, and productive cough 3 Includes arthralgia, pain in extremity, myalgia, non-cardiac chest pain, neck pain, musculoskeletal chest pain, and back pain 4 Includes rash maculo-papular, rash, dermatitis acneiform, eczema, skin exfoliation, and drug eruption 5 Includes vertigo and dizziness 6 Includes pulmonary hemorrhage, hemoptysis, conjunctival hemorrhage, epistaxis, hematuria, rectal hemorrhage, and laryngeal hemorrhage 7 Includes atrial fibrillation, sinus bradycardia, ventricular tachycardia, and sinus tachycardia 8 Includes hypothyroidism and blood thyroid stimulating hormone increased |
||
Table 22: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients with ASPS Receiving Intravenous Atezolizumab in ML39345
| Laboratory Abnormality1 | Intravenous Atezolizumab2 | |
| All Grades (%) | Grades 3-4 (%) | |
| Hematology | ||
| Decreased Hemoglobin | 63 | 0 |
| Decreased Platelets | 27 | 0 |
| Increased Platelets | 29 | 0 |
| Chemistry | ||
| Increased Alkaline Phosphatase | 29 | 0 |
| Decreased Amylase | 40 | 0 |
| Increased Amylase | 20 | 20 |
| Decreased Bilirubin | 49 | 0 |
| Decreased Calcium | 47 | 0 |
| Increased Calcium | 25 | 14 |
| Decreased Glucose | 33 | 0 |
| Increased Glucose | 78 | 0 |
| Decreased Glucose (fasting) | 25 | 0 |
| Decreased Magnesium | 21 | 0 |
| Increased Magnesium | 26 | 26 |
| Increased AST | 39 | 2 |
| Increased ALT | 33 | 2 |
| Decreased Sodium | 43 | 0 |
| Increased Lipase | 25 | 25 |
| 1 Laboratory tests which do not have NCI CTCAE grading criteria are also included for All Grade assessments, which were performed by comparing to respective lab normal ranges 2 The denominators used to calculate the rate varied from 4–49 for all tests of interest based on the number of patients with a baseline value and at least one on-study laboratory measurement available |
||
The following adverse reactions have been identified during post-approval use of intravenous atezolizumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
No Information provided
Included as part of the PRECAUTIONS section.
TECENTRIQ HYBREZA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatal immune-mediated reactions.
Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting a PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.
Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see DOSAGE AND ADMINISTRATION]. In general, if TECENTRIQ HYBREZA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.
TECENTRIQ HYBREZA can cause immune-mediated pneumonitis, including fatal adverse reactions. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation.
Immune-mediated pneumonitis occurred in 2% (5/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see ADVERSE REACTIONS], including Grade 2 (0.8%), and Grade 1 (1.2%) events. Pneumonitis led to the withholding of TECENTRIQ HYBREZA in one patient.
Systemic corticosteroids were required in 40% (2/5) patients with pneumonitis who received TECENTRIQ HYBREZA as monotherapy. Pneumonitis resolved in both patients. The single patient in whom TECENTRIQ HYBREZA was withheld for pneumonitis reinitiated TECENTRIQ HYBREZA after symptom improvement.
Intravenous Atezolizumab In Combination With Cobimetinib And Vemurafenib
Immune-mediated pneumonitis occurred in 13% (29/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see ADVERSE REACTIONS], including Grade 3 (1.3%) and Grade 2 (7%) adverse reactions. Pneumonitis led to permanent discontinuation of intravenous atezolizumab in 2.6% of patients and withholding of intravenous atezolizumab in 7.4% of patients.
Systemic corticosteroids were required in 55% (16/29) of patients with pneumonitis. Pneumonitis resolved in 97% of the 29 patients. Of the 17 patients in whom intravenous atezolizumab was withheld for pneumonitis, 10 reinitiated intravenous atezolizumab after symptom improvement; of these, 50% had recurrence of pneumonitis.
TECENTRIQ HYBREZA can cause immune-mediated colitis, including Grade 3 adverse reactions. Colitis can present with diarrhea, abdominal pain, and lower gastrointestinal bleeding. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.
TECENTRIQ HYBREZA can cause immune-mediated hepatitis, including fatal adverse reactions.
Immune-mediated hepatitis occurred in 1.2% (3/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see ADVERSE REACTIONS], including Grade 1 (0.4%) and Grade 3 (0.8%) events. Hepatitis led to the withholding of TECENTRIQ HYBREZA in 0.4% of patients.
Systemic corticosteroids were required in 67% (2/3) of patients with hepatitis who received TECENTRIQ HYBREZA as monotherapy. Hepatitis resolved in 1 of the 3 patients.
Intravenous Atezolizumab In Combination With Cobimetinib And Vemurafenib
Immune-mediated hepatitis occurred in 6.1% (14/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see ADVERSE REACTIONS], including Grade 4 (1.3%), Grade 3 (1.7%) and Grade 2 (1.3%) adverse reactions. Hepatitis led to permanent discontinuation of intravenous atezolizumab in 2.2% and withholding of intravenous atezolizumab in 1.7% of patients.
Systemic corticosteroids were required in 50% (7/14) of patients with hepatitis. Hepatitis resolved in 93% of the 14 patients. Of the 4 patients in whom intravenous atezolizumab was withheld for hepatitis, 3 reinitiated intravenous atezolizumab after symptom improvement; of these, 33% had recurrence of hepatitis.
Adrenal Insufficiency
TECENTRIQ HYBREZA can cause primary or secondary adrenal insufficiency, including Grade 3 adverse reactions. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see DOSAGE AND ADMINISTRATION)].
Immune-mediated adrenal insufficiency occurred in 0.8% (2/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see ADVERSE REACTIONS], including Grade 2 (0.4%) adverse reactions. Adrenal insufficiency led to the withholding of TECENTRIQ HYBREZA in both patients. Systemic corticosteroids were required in 50% (½) of patients with adrenal insufficiency who received TECENTRIQ HYBREZA as monotherapy; this single patient remained on systemic corticosteroids.
Hypophysitis
TECENTRIQ HYBREZA can cause immune-mediated hypophysitis, including Grade 2 adverse reactions. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see DOSAGE AND ADMINISTRATION].
Immune-mediated hypophysitis occurred in 0.4% (1/247) of patients with locally advanced or metastatic NSCLC in the IMscin001 trial [see ADVERSE REACTIONS] receiving TECENTRIQ HYBREZA as monotherapy, including Grade 1 (0.4%) adverse reactions. Hypophysitis led to the withholding of TECENTRIQ HYBREZA in this patient.
Thyroid Disorders
TECENTRIQ HYBREZA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or medical management for hyperthyroidism as clinically indicated. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see DOSAGE AND ADMINISTRATION].
Thyroiditis
Immune-mediated thyroiditis occurred in 0.8% (2/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see ADVERSE REACTIONS], including Grade 2 (0.4%) adverse reactions. Thyroiditis resolved in 50% of patients.
Hyperthyroidism
Immune-mediated hyperthyroidism occurred in 2% (5/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see ADVERSE REACTIONS], including Grade 2 (1.2%) adverse reactions. Hyperthyroidism led to withholding of TECENTRIQ HYBREZA in 0.8% of patients.
Anti-thyroid therapy was required in 40% (2/5) of patients with hyperthyroidism who received TECENTRIQ HYBREZA as monotherapy. Of these 2 patients, one remained on anti-thyroid treatment. Of the 2 patients in whom TECENTRIQ HYBREZA was withheld for hyperthyroidism, 1 patient reinitiated TECENTRIQ HYBREZA; this patient did not have recurrence of hyperthyroidism.
Intravenous Atezolizumab In Combination With Cobimetinib And Vemurafenib
Hyperthyroidism occurred in 19% (43/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see ADVERSE REACTIONS], including Grade 3 (0.9%) and Grade 2 (7.8%) adverse reactions. Hyperthyroidism led to permanent discontinuation of intravenous atezolizumab in 0.4% and withholding of intravenous atezolizumab in 10% of patients. Antithyroid therapy was required in 53% (23/43) of patients with hyperthyroidism. Of these 23 patients, the majority remained on antithyroid treatment. Of the 24 patients in whom intravenous atezolizumab was withheld for hyperthyroidism, 18 patients reinitiated intravenous atezolizumab; of these, 28% had recurrence of hyperthyroidism.
Hypothyroidism
TECENTRIQ HYBREZA can cause immune-mediated hypothyroidism, including Grade 4 adverse reactions. Immune-mediated hypothyroidism occurred in 10% (25/247) of patients with locally advanced or metastatic NSCLC who received TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see ADVERSE REACTIONS].
Hormone replacement was required in 68% (17/25) of patients with hypothyroidism who received TECENTRIQ HYBREZA as monotherapy. Two patients with hypothyroidism remained on thyroid hormone replacement.
Intravenous Atezolizumab In Combination With Platinum-based Chemotherapy
Hypothyroidism occurred in 11% (277/2421) of patients with NSCLC (N = 2223) or SCLC (N = 198) enrolled in five randomized, active-controlled trials, including IMpower150, IMpower130 and IMpower133 receiving intravenous atezolizumab in combination with platinum-based chemotherapy, including Grade 4 (< 0.1%), Grade 3 (0.3%), and Grade 2 (5.7%) adverse reactions. Hypothyroidism led to permanent discontinuation of intravenous atezolizumab in 0.1% and withholding of intravenous atezolizumab in 1.6% of patients.
Hormone replacement therapy was required in 71% (198/277) of patients with hypothyroidism. The majority of patients with hypothyroidism remained on thyroid hormone replacement. Of the 39 patients in whom intravenous atezolizumab was withheld for hypothyroidism, 9 reinitiated intravenous atezolizumab after symptom improvement.
Intravenous Atezolizumab In Combination With Cobimetinib And Vemurafenib
Hypothyroidism occurred in 26% (60/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see ADVERSE REACTIONS], including Grade 2 (9.1%) adverse reactions. Hypothyroidism led to withholding of intravenous atezolizumab in 2.6% of patients. Hormone replacement therapy was required in 52% (31/60) of patients with hypothyroidism. The majority of patients with hypothyroidism remained on thyroid hormone replacement. Of the 6 patients in whom intravenous atezolizumab was withheld for hypothyroidism, 4 reinitiated intravenous atezolizumab after symptom improvement. The majority of patients with hypothyroidism required long term thyroid replacement.
Type 1 Diabetes Mellitus, Which Can Present With Diabetic Ketoacidosis
TECENTRIQ HYBREZA can cause type 1 diabetes mellitus, including Grade 3 adverse reactions and diabetic ketoacidosis. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see DOSAGE AND ADMINISTRATION].
TECENTRIQ HYBREZA can cause immune-mediated nephritis, including Grade 3 adverse reactions.
Intravenous Atezoliuzmab In Combination With Cobimetinib And Vemurafenib
Immune-mediated nephritis with renal dysfunction occurred in 1.3% (3/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see ADVERSE REACTIONS], including Grade 2 (1.3%) adverse reactions. Nephritis led to permanent discontinuation of intravenous atezolizumab in 0.4% and withholding of intravenous atezolizumab in 0.9% of patients.
Systemic corticosteroids were required in 67% (2/3) of patients with nephritis. Nephritis resolved in all 3 of these patients. Of the 2 patients in whom intravenous atezolizumab was withheld for nephritis, both reinitiated intravenous atezolizumab after symptom improvement and neither had recurrence of nephritis.
TECENTRIQ HYBREZA can cause immune-mediated rash or dermatitis, including Grade 3 and fatal adverse reactions. Exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see DOSAGE AND ADMINISTRATION].
One fatal case of an immune-mediated dermatologic adverse reaction, due to TEN, occurred (0.4%, 1/247) in patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see ADVERSE REACTIONS].
The following clinically significant immune-mediated adverse reactions occurred at an incidence of < 1% (unless otherwise noted) in patients receiving intravenous atezolizumab or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.
TECENTRIQ HYBREZA can cause severe or life-threatening infusion-related reactions, including Grade 3 adverse reactions. Monitor for signs and symptoms of infusion-related reactions. Pause, slow the rate of, or permanently discontinue TECENTRIQ HYBREZA based on the severity [see DOSAGE AND ADMINISTRATION]. For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses.
Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockage and allogeneic HSCT.
Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefits versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT.
Based on its mechanism of action, TECENTRIQ HYBREZA can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ HYBREZA in pregnant women. Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus resulting in fetal death.
Verify pregnancy status of females of reproductive potential prior to initiating TECENTRIQ HYBREZA. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ HYBREZA and for 5 months after the last dose [see Use In Specific Populations].
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Inform patients of the risk of immune-mediated adverse reactions that may require corticosteroid treatment and interruption or discontinuation of TECENTRIQ HYBREZA, including:
Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions [see WARNINGS AND PRECAUTIONS].
Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefits versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT [see WARNINGS AND PRECAUTIONS].
Advise females of reproductive potential that TECENTRIQ HYBREZA can cause harm to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see WARNINGS AND PRECAUTIONS, Use In Specific Populations].
Advise females of reproductive potential to use effective contraception during treatment and for 5 months after the last dose of TECENTRIQ HYBREZA [see Use In Specific Populations].
Advise female patients not to breastfeed while taking TECENTRIQ HYBREZA and for 5 months after the last dose [see Use In Specific Populations]. TECENTRIQ HYBREZATM (atezolizumab and hyaluronidase-tqjs)
No studies have been performed to test the potential of atezolizumab for carcinogenicity or genotoxicity.
Animal fertility studies have not been conducted with atezolizumab; however, an assessment of the male and female reproductive organs was included in a 26-week, repeat-dose toxicity study in cynomolgus monkeys. Weekly administration of atezolizumab to female monkeys at the highest dose tested caused an irregular menstrual cycle pattern and a lack of newly formed corpora lutea in the ovaries. This effect occurred at an estimated AUC approximately 6 times the AUC in patients receiving the recommended intravenous atezolizumab dose and was reversible. There was no effect on the male monkey reproductive organs.
Hyaluronidases are found in most tissues of the body. Long-term animal studies have not been performed to assess the carcinogenic or mutagenic potential of hyaluronidase. In addition, when up to 220,000 units/kg of subcutaneous hyaluronidase (recombinant human) was administered to cynomolgus monkeys for 39 weeks, which is > 223 times higher than the human recommended dose for hyaluronidase, no evidence of toxicity to the male or female reproductive system was found through periodic monitoring of in-life parameters (e.g., semen analyses, hormone levels, menstrual cycles, and also from gross pathology, histopathology and organ weight data).
Based on its mechanism of action [see CLINICAL PHARMACOLOGY], TECENTRIQ HYBREZA can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ HYBREZA in pregnant women.
Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus resulting in fetal death (see Data). Advise females of reproductive potential of the potential risk to a fetus [see WARNINGS AND PRECAUTIONS].
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Animal Data
TECENTRIQ HYBREZA for subcutaneous injection contains atezolizumab and hyaluronidase [see DESCRIPTION ].
Atezolizumab: Animal reproduction studies have not been conducted with atezolizumab to evaluate its effect on reproduction and fetal development. A literature-based assessment of the effects on reproduction demonstrated that a central function of the PD-L1/PD-1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to a fetus. Blockage of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to a fetus and to result in an increase in fetal loss; therefore, potential risks of administering atezolizumab during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-L1/PD-1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to atezolizumab may increase the risk of developing immune-mediated disorders or altering the normal immune response.
Hyaluronidase: In an embryo-fetal study, mice were dosed daily by subcutaneous injection during the period of organogenesis with hyaluronidase (recombinant human) at dose levels up to 2,200,000 U/kg, which is > 2,400 times higher than the human dose. The study found no evidence of teratogenicity. Reduced fetal weight and increased numbers of fetal resorptions were observed, with no effects found at a daily dose of 360,000 U/kg, which is > 400 times higher than the human dose.
In a peri-and post-natal reproduction study, mice have been dosed daily by subcutaneous injection, with hyaluronidase (recombinant human) from implantation through lactation and weaning at dose levels up to 1,100,000 U/kg, which is > 1,200 times higher than the human dose. The study found no adverse effects on sexual maturation, learning and memory or fertility of the offspring.
There is no information regarding the presence of atezolizumab or hyaluronidase in human milk or its effects on the breastfed child, or on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to TECENTRIQ HYBREZA are unknown. Because of the potential for serious adverse reactions in breastfed children from TECENTRIQ HYBREZA, advise women not to breastfeed during treatment with TECENTRIQ HYBREZA and for 5 months after the last dose.
Based on its mechanism of action, TECENTRIQ HYBREZA can cause fetal harm when administered to a pregnant woman [see Use In Specific Populations].
Verify pregnancy status in females of reproductive potential prior to initiating TECENTRIQ HYBREZA [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
Females: Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ HYBREZA and for 5 months following the last dose.
Females
Based on animal studies, TECENTRIQ HYBREZA may impair fertility in females of reproductive potential while receiving TECENTRIQ HYBREZA treatment [see Nonclinical Toxicology].
The safety and effectiveness of TECENTRIQ HYBREZA have not been established in pediatric patients.
Of 247 adult patients treated with TECENTRIQ HYBREZA as monotherapy in IMscin001, 45% were 65 years and over and 10% were 75 years and over. No overall differences in safety or effectiveness of TECENTRIQ HYBREZA have been observed between patients aged 65 years or older and younger adult patients.
The safety of TECENTRIQ HYBREZA as monotherapy or in combination with other antineoplastic drugs for its approved indications [see INDICATIONS AND USAGE] has been established in adequate and well-controlled studies of intravenous atezolizumab as a single agent and in combination with other antineoplastic drugs. Below is a description of geriatric use information from the intravenous atezolizumab studies.
No overall differences in safety or effectiveness were observed between intravenous atezolizumab-treated patients aged 65 years or older and younger adult patients.
No Information provided
TECENTRIQ HYBREZA is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.
PD-L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T-cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.
Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth.
In mouse models of cancer, dual inhibition of the PD-1/PD-L1 and MAPK pathways suppresses tumor growth and improves tumor immunogenicity through increased antigen presentation and T-cell infiltration and activation compared to targeted therapy alone.
Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days.
Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. In the doses administered, hyaluronidase in TECENTRIQ HYBREZA acts transiently and locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.
The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of atezolizumab and hyaluronidase have not been fully characterized.
When comparing atezolizumab exposure following subcutaneous TECENTRIQ HYBREZA to that of intravenous atezolizumab in Study IMscin001 [see Clinical Studies], the geometric mean ratio (GMR) (90% CI) for Cycle 1 Ctrough was 1.05 (0.88, 1.24) and AUC0-21days was 0.87 (0.83, 0.92); the steady state Ctrough was 1.15 (1.05, 1.26) and AUC was 1.01 (0.94, 1.08).
Steady-state was achieved 6 to 9 weeks. The systemic accumulation ratio following administration of the approved recommended dosage of TECENTRIQ HYBREZA was 2.2.
The mean absolute bioavailability (CV%) of atezolizumab was 72% (83%) and the median time (range) to reach maximum atezolizumab concentration (Tmax) was 4.5 (2.2, 9) days.
The volume of distribution of atezolizumab at steady state was 6.9 L.
The atezolizumab clearance (CV%) was 0.2 L/day (29%) and the terminal half-life was 27 days. Atezolizumab clearance decreased over time, with a mean maximal reduction (CV%) from baseline value of 17% (41%); this decrease in clearance is not considered clinically significant.
No clinically significant differences in the pharmacokinetics of atezolizumab were observed based on age, body weight, sex, albumin levels, tumor burden, region, race, mild or moderate renal impairment (estimated glomerular filtration rate 30 to 89 mL/minute/1.73 m2), mild hepatic impairment (bilirubin ≤ ULN and AST > ULN or bilirubin > 1 to 1.5 × ULN and any AST), moderate hepatic impairment (bilirubin >1.5 to 3× ULN and any AST), level of PD-L1 expression, and performance status.
The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of TECENTRIQ HYBREZA or of other atezolizumab products or hyaluronidase products.
During the first year of treatment in the Study IMscin001 [see Clinical Studies], the incidence of anti-atezolizumab antibodies was 20% (43/221) and the incidence of neutralizing antibodies (NAb) in ADA-positive patients was 54% (21/39) for TECENTRIQ HYBREZA. The corresponding incidence of ADA was 14% (15/108) and NAb was 60% (9/15) for intravenous atezolizumab.
In Study IMscin001, atezolizumab clearance increased by 29% in patients who received TECENTRIQ HYBREZA and who tested positive for ADA, compared to patients who tested negative for ADA; this change in clearance is not expected to be clinically significant. Because of limited immunogenicity data the effect of anti-atezolizumab antibodies on the effectiveness of TECENTRIQ HYBREZA is unknown. There was no identified clinically significant effect of anti-atezolizumab antibodies on the safety of TECENTRIQ HYBREZA during the first 6 months of treatment.
In Study IMscin001, the incidence of anti-rHuPH20 antibodies was 5.4% (12/224) and the incidence of NAb was 0% (0/12). Because of the low occurrence of anti-rHuPH20 antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics and/or safety of hyaluronidase in TECENTRIQ HYBREZA is unknown.
During the first year of treatment with intravenous atezolizumab across clinical studies of patients with NSCLC, SCLC, HCC, and melanoma 13% to 36% of patients developed anti-atezolizumab antibodies. Across clinical studies, the NAb incidence in ADA-positive patients was 24% to 83%.
In OAK and IMbrave150, exploratory analyses showed that the subset of patients who were ADA-positive appeared to have less efficacy (effect on overall survival) as compared to patients who tested negative for ADA [see Clinical Studies]. In study IMpower150, the impact of ADA on efficacy did not appear to be clinically significant [see Clinical Studies]. In the remaining studies, there is insufficient information to characterize the effect of ADA on efficacy.
Median atezolizumab clearance in patients who tested positive for anti-atezolizumab antibodies (ADA) was 19% (range of 18% to 49%) higher as compared to atezolizumab clearance in patients who tested negative for ADA; this change in clearance is not expected to be clinically significant. The presence of ADA did not have a clinically significant effect on the incidence or severity of adverse reactions. The effect of NAb on atezolizumab exposure and safety did not appear to be clinically significant. The effect of NAb on key efficacy endpoints is uncertain due to small sample sizes.
In animal models, inhibition of PD-L1/PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. Mycobacterium tuberculosis-infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-L1 and PD-1 knockout mice and mice receiving PD-L1 blocking antibody have also shown decreased survival following infection with lymphocytic choriomeningitis virus.
IMscin001 (NCT03735121) was an open-label, multi-center, international, randomized study conducted in adult patients with locally advanced or metastatic NSCLC who were not exposed to cancer immunotherapy and who have disease progression following platinum-based chemotherapy. Patients were excluded if they had a history of autoimmune disease; active or corticosteroid-dependent brain metastases; received a live, attenuated vaccine within 4 weeks prior to randomization; or received systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive drugs within 2 weeks prior to randomization. A total of 371 patients were randomized 2:1 to receive either TECENTRIQ HYBREZA (containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase) administered subcutaneously in the thigh every 3 weeks (n = 247) or intravenous atezolizumab 1,200 mg every 3 weeks (n = 124) until disease progression or unacceptable toxicity.
The primary outcome measure was atezolizumab exposure (Ctrough and AUC0-21days) of subcutaneous TECENTRIQ HYBREZA as compared to intravenous atezolizumab [see CLINICAL PHARMACOLOGY]. Additional descriptive efficacy outcome measures were overall response rate (ORR), progression-free survival (PFS) and overall survival (OS).
The median age was 64 years (range: 27 to 85); 69% were male; 67% were White, 22% were Asian, and 0.8% were Black or African American; 74% were non-Hispanic or Latino; 26% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 74% had an ECOG PS of 1; and 70% of patients were current or previous smokers. Sixty-five percent of patients had non-squamous histology, 5% had known EGFR mutations, 1.6% had known ALK rearrangements, 36% had known PD-L1 positive tumors, 16% had asymptomatic CNS metastases at baseline. Eighty percent of patients had received only one prior therapeutic regimen for NSCLC.
At the primary analysis, the confirmed ORR was 9% (95% CI: 5, 13) in the subcutaneous TECENTRIQ HYBREZA arm and 8% (95% CI: 4, 14) in the intravenous atezolizumab arm. After further follow up, no notable differences in PFS and OS were observed between patients who received subcutaneous TECENTRIQ HYBREZA and patients who received intravenous atezolizumab.
The effectiveness of TECENTRIQ HYBREZA has been established for:
Use of TECENTRIQ HYBREZA for these NSCLC indications is supported by evidence from the adequate and well-controlled studies conducted with intravenous atezolizumab in these NSCLC populations and pharmacokinetics data that demonstrated comparable exposures to atezolizumab between TECENTRIQ HYBREZA and intravenous atezolizumab in the IMscin001 trial [see ADVERSE REACTIONS, CLINICAL PHARMACOLOGY, and Clinical Studies]. Below is a description of the efficacy results of these adequate and well-controlled studies of intravenous atezolizumab in these NSCLC populations.
IMpower010
The efficacy of intravenous atezolizumab was evaluated in IMpower010 (NCT02486718), a multi-center, randomized, open-label trial for the adjuvant treatment of patients with NSCLC who had complete tumor resection and were eligible to receive cisplatin-based adjuvant chemotherapy. Eligible patients were required to have Stage IB (tumors ≥ 4 cm) – Stage IIIA NSCLC per the Union for International Cancer Control/American Joint Committee on Cancer staging system, 7th edition. Patients were excluded if they had a history of autoimmune disease; a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis; administration of a live, attenuated vaccine within 28 days prior to randomization; administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization.
A total of 1005 patients who had complete tumor resection and received cisplatin-based adjuvant chemotherapy were randomized (1:1) to receive intravenous atezolizumab 1200 mg intravenous infusion every 3 weeks for 16 cycles, unless disease recurrence or unacceptable toxicity occurred, or best supportive care (BSC). Randomization was stratified by sex, stage of disease, histology, and PD-L1 expression.
Tumor assessments were conducted at baseline of the randomization phase and every 4 months for the first year following Cycle 1, Day 1 and then every 6 months until year five, then annually thereafter.
The median age was 62 years (range: 26 to 84), and 67% of patients were male. The majority of patients were White (73%) and Asian (24%). Most patients were current or previous smokers (78%) and baseline ECOG performance status in patients was 0 (55%) or 1 (44%). Overall, 12% of patients had Stage IB, 47% had Stage II and 41% had Stage IIIA disease. PD-L1 expression, defined as the percentage of tumor cells expressing PD-L1 as measured by the VENTANA PD-L1 (SP263) assay, was ≥ 1% in 53% of patients, < 1% in 44% and unknown in 2.6%.
The primary efficacy outcome measure was disease-free survival (DFS) as assessed by the investigator. The primary efficacy analysis population (n = 476) was patients with Stage II – IIIA NSCLC with PD-L1 expression on ≥ 1% of tumor cells (PD-L1 ≥ 1% TC). DFS was defined as the time from the date of randomization to the date of occurrence of any of the following: first documented recurrence of disease, new primary NSCLC, or death due to any cause, whichever occurred first. A key secondary efficacy outcome measure was overall survival (OS) in the intent-to-treat population.
At the time of the interim DFS analysis, the study demonstrated a statistically significant improvement in DFS in the PD-L1 ≥ 1% TC, Stage II – IIIA patient population.
Efficacy results are presented in Table 23 and Figure 1.
Table 23: Efficacy Results from IMpower010 in Patients with Stage II - IIIA NSCLC with PD-L1 expression ≥ 1% TC
| Arm A: Intravenous Atezolizumab N = 248 |
Arm B: Best Supportive Care N = 228 |
|
| Disease-Free Survival | ||
| Number of events (%) | 88 (35) | 105 (46) |
| Median, months (95% CI) | NR (36.1, NE) | 35.3 (29.0, NE) |
| Hazard ratio1 (95% CI) | 0.66 (0.50, 0.88) | |
| p-value | 0.004 | |
| CI = Confidence interval, NE = Not estimable, NR = Not reached 1 Stratified by stage, sex, and histology |
||
In a pre-specified secondary subgroup analysis of patients with PD-L1 TC ≥ 50% Stage II – IIIA NSCLC (n = 229), the median DFS was not reached (95% CI: 42.3 months, NE) for patients in the intravenous atezolizumab arm and was 35.7 months (95% CI: 29.7, NE) for patients in the best supportive care arm, with a HR of 0.43 (95% CI: 0.27, 0.68). In an exploratory subgroup analysis of patients with PD-L1 TC 1-49% Stage II – IIIA NSCLC (n = 247), the median DFS was 32.8 months (95% CI:29.4, NE) for patients in the intravenous atezolizumab arm and 31.4 months (95% CI: 24.0, NE) for patients in the best supportive care arm, with a HR of 0.87 (95% CI: 0.60, 1.26).
Figure 1: Kaplan-Meier Plot of Disease-Free Survival in IMpower010 in Patients with Stage II – IIIA NSCLC with PD-L1 expression ≥ 1% TC
 |
At the time of the DFS interim analysis, 19% of patients in the PD-L1 ≥1% TC Stage II – IIIA patient population had died. An exploratory analysis of OS in this population resulted in a stratified HR of 0.77 (95% CI: 0.51, 1.17).
IMpower110
The efficacy of intravenous atezolizumab was evaluated in IMpower110 (NCT02409342), a multicenter, international, randomized, open-label trial in patients with stage IV NSCLC whose tumors express PD-L1 (PD-L1 stained ≥ 1% of tumor cells [TC ≥ 1%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 1% of the tumor area [IC ≥ 1%]), who had received no prior chemotherapy for metastatic disease. PD-L1 tumor status was determined based on immunohistochemistry (IHC) testing using the VENTANA PD-L1 (SP142) Assay. The evaluation of efficacy is based on the subgroup of patients with high PD-L1 expression (TC ≥ 50% or IC ≥ 10%), excluding those with EGFR or ALK genomic tumor aberrations. The trial excluded patients with a history of autoimmune disease, administration of a live attenuated vaccine within 28 days prior to randomization, active or untreated CNS metastases, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization.
Randomization was stratified by sex, ECOG performance status, histology (non-squamous vs. squamous) and PD-L1 expression (TC ≥ 1% and any IC vs. TC < 1% and IC ≥ 1%). Patients were randomized (1:1) to receive one of the following treatment arms:
Arm B platinum-based chemotherapy regimens for non-squamous NSCLC consisted of cisplatin (75 mg/m²) and pemetrexed (500 mg/m²) OR carboplatin (AUC 6 mg/mL/min) and pemetrexed (500 mg/m²) on Day 1 of each 21-day cycle for a maximum of 4 or 6 cycles followed by pemetrexed (500 mg/m²) until disease progression or unacceptable toxicity.
Arm B platinum-based chemotherapy regimens for squamous NSCLC consisted of cisplatin (75 mg/m²) on Day 1 with gemcitabine (1250 mg/m2) on Days 1 and 8 of each 21-day cycle OR carboplatin (AUC 5 mg/mL/min) on Day 1 with gemcitabine (1000 mg/m2) on Days 1 and 8 of each 21-day cycle for a maximum of 4 or 6 cycles followed by best supportive care until disease progression or unacceptable toxicity.
Administration of intravenous atezolizumab was permitted beyond RECIST-defined disease progression. Tumor assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Tumor specimens were evaluated prospectively using the VENTANA PD-L1 (SP142) Assay at a central laboratory and the results were used to define subgroups for pre-specified analyses.
The major efficacy outcome measure was overall survival (OS) sequentially tested in the following subgroups of patients, excluding those with EGFR or ALK genomic tumor aberrations: TC ≥ 50% or IC ≥ 10%; TC ≥ 5% or IC ≥ 5%; and TC ≥ 1% or IC ≥ 1%.
Among the 205 chemotherapy-naïve patients with stage IV NSCLC with high PD-L1 expression (TC ≥ 50% or IC ≥ 10%) excluding those with EGFR or ALK genomic tumor aberrations, the median age was 65.0 years (range: 33 to 87), and 70% of patients were male. The majority of patients were White (82%) and Asian (17%). Baseline ECOG performance status was 0 (36%) or 1 (64%); 88% were current or previous smokers; and 76% of patients had non-squamous disease while 24% of patients had squamous disease.
The trial demonstrated a statistically significant improvement in OS for patients with high PD-L1 expression (TC ≥ 50% or IC ≥ 10%) at the time of the OS interim analysis. There was no statistically significant difference in OS for the other two PD-L1 subgroups (TC ≥ 5% or IC ≥ 5%; and TC ≥ 1% or IC ≥ 1%) at the interim or final analyses. Efficacy results for patients with
NSCLC with high PD-L1 expression are presented in Table 24 and Figure 2.
Table 24: Efficacy Results from IMpower110 in Patients with NSCLC with High PD-L1 Expression (TC ≥ 50% or IC ≥ 10%) and without EGFR or ALK Genomic Tumor Aberrations
| Arm A: Intravenous Atezolizumab N = 107 |
Arm B: Platinum-Based Chemotherapy N = 98 |
|
| Overall Survival1 | ||
| Deaths (%) | 44 (41%) | 57 (58%) |
| Median, months | 20.2 | 13.1 |
| (95% CI) | (16.5, NE) | (7.4, 16.5) |
| Hazard ratio2 (95% CI) | 0.59 (0.40, 0.89) | |
| p-value3 | 0.01064 | |
| 1 Based on OS interim analysis. The median survival follow-up time in patients was 15.7 months 2 Stratified by sex and ECOG performance status 3 Based on the stratified log-rank test compared to Arm A 4 Compared to the allocated alpha of 0.0413 (two-sided) for this interim analysis CI = confidence interval; NE = not estimable |
||
Figure 2: Kaplan-Meier Plot of Overall Survival in IMpower110 in Patients with NSCLC with High PD-L1 Expression (TC ≥ 50% or IC ≥ 10%) and without EGFR or ALK Genomic Tumor Aberrations
 |
Investigator-assessed PFS showed an HR of 0.63 (95% CI: 0.45, 0.88), with median PFS of 8.1 months (95% CI: 6.8, 11.0) in the intravenous atezolizumab arm and 5 months (95% CI: 4.2, 5.7) in the platinum-based chemotherapy arm. The investigator-assessed confirmed ORR was 38% (95% CI: 29%, 48%) in the intravenous atezolizumab arm and 29% (95% CI: 20%, 39%) in the platinum-based chemotherapy arm.
IMpower150
The efficacy of intravenous atezolizumab with bevacizumab, paclitaxel, and carboplatin was evaluated in IMpower150 (NCT02366143), a multicenter, international, randomized (1:1:1), open-label trial in patients with metastatic non-squamous NSCLC. Patients with stage IV non-squamous NSCLC who had received no prior chemotherapy for metastatic disease but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene (tGE) status and ECOG performance status 0 or 1 were eligible. The trial excluded patients with a history of autoimmune disease, administration of a live attenuated vaccine within 28 days prior to randomization, active or untreated CNS metastases, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization, or clear tumor infiltration into the thoracic great vessels or clear cavitation of pulmonary lesions as seen on imaging. Randomization was stratified by sex, presence of liver metastases, and PD-L1 expression status on tumor cells (TC) and tumor-infiltrating immune cells (IC) as follows: TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1. Patients were randomized to one of the following three treatment arms:
Patients who had not experienced disease progression following the completion or cessation of platinum-based chemotherapy, received:
Tumor assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Tumor specimens were evaluated prior to randomization for PD-L1 tumor expression using the VENTANA PD-L1 (SP142) assay at a central laboratory. Tumor tissue was collected at baseline for expression of tGE signature and evaluation was performed using a clinical trial assay in a central laboratory prior to the analysis of efficacy outcome measures.
Major efficacy outcome measures for comparison of Arms B and C were progression free survival (PFS) by RECIST v1.1 in the tGE-WT (patients with high expression of T-effector gene signature [tGE], excluding those with EGFR- and ALK-positive NSCLC [WT]) and in the ITT-WT subpopulations and overall survival (OS) in the ITT-WT subpopulation. Additional efficacy outcome measures for comparison of Arms B and C or Arms A and C were PFS and OS in the ITT population, OS in the tGE-WT subpopulation, and ORR/DoR in the tGE-WT and ITT-WT subpopulations.
A total of 1202 patients were enrolled across the three arms of whom 1045 were in the ITT-WT subpopulation and 447 were in the tGE-WT subpopulation. The demographic information is limited to the 800 patients enrolled in Arms B and C where efficacy has been demonstrated. The median age was 63 years (range: 31 to 90), and 60% of patients were male. The majority of patients were White (82%), 13% of patients were Asian, 10% were Hispanic, and 2% of patients were Black. Clinical sites in Asia (enrolling 13% of the study population) received paclitaxel at a dose of 175 mg/m2 while the remaining 87% received paclitaxel at a dose of 200 mg/m2. Approximately 14% of patients had liver metastases at baseline, and most patients were current or previous smokers (80%). Baseline ECOG performance status was 0 (43%) or 1 (57%). PD-L1 was TC3 and any IC in 12%, TC0/1/2 and IC2/3 in 13%, and TC0/1/2 and IC0/1 in 75%. The demographics for the 696 patients in the ITT-WT subpopulation were similar to the ITT population except for the absence of patients with EGFR- or ALK-positive NSCLC.
The trial demonstrated a statistically significant improvement in PFS between Arms B and C in both the tGE-WT and ITT-WT subpopulations, but did not demonstrate a significant difference for either subpopulation between Arms A and C based on the final PFS analyses. In the interim analysis of OS, a statistically significant improvement was observed for Arm B compared to Arm C, but not for Arm A compared to Arm C. Efficacy results for the ITT-WT subpopulation are presented in Table 25 and Figure 3.
Table 25: Efficacy Results in ITT-WT Population in IMpower150
| Arm C: Bevacizumab, Paclitaxel and Carboplatin N = 337 |
Arm B: Intravenous Atezolizumab with Bevacizumab, Paclitaxel, and Carboplatin N = 359 |
Arm A: Intravenous Atezolizumab with Paclitaxel, and Carboplatin N = 349 |
|
| Overall Survival1 | |||
| Deaths (%) | 197 (59%) | 179 (50%) | 179 (51%) |
| Median, months | 14.7 | 19.2 | 19.4 |
| (95% CI) | (13.3, 16.9) | (17.0, 23.8) | (15.7, 21.3) |
| Hazard ratio2 (95% CI) | --- | 0.78 (0.64, 0.96) |
0.84 (0.72, 1.08) |
| p-value3 | --- | 0.0164 | 0.2045 |
| Progression-Free Survival6 | |||
| Number of events (%) | 247 (73%) | 247 (69%) | 245 (70%) |
| Median, months | 7.0 | 8.5 | 6.7 |
| (95% CI) | (6.3, 7.9) | (7.3, 9.7) | (5.6, 6.9) |
| Hazard ratio2 (95% CI) | --- | 0.71 (0.59, 0.85) |
0.94 (0.79, 1.13) |
| p-value3 | --- | 0.00027 | 0.5219 |
| Objective Response Rate6 | |||
| Number of responders (%) | 142 (42%) | 196 (55%) | 150 (43%) |
| (95% CI) | (37, 48) | (49, 60) | (38, 48) |
| Complete Response | 3 (1%) | 14 (4%) | 9 (3%) |
| Partial Response | 139 (41%) | 182 (51%) | 141 (40%) |
| Duration of Response6 | n = 142 | n = 196 | n = 150 |
| Median, months | 6.5 | 10.8 | 9.5 |
| (95% CI) | (5.6, 7.6) | (8.4, 13.9) | (7.0, 13.0) |
| 1 Based on OS interim analysis 2 Stratified by sex, presence of liver metastases, and PD-L1 expression status on TC and IC 3 Based on the stratified log-rank test compared to Arm C 4 Compared to the allocated α=0.0174 (two sided) for this interim analysis 5 Compared to the allocated α=0.0128 (two sided) for this interim analysis 6 As determined by independent review facility (IRF) per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1) 7 Compared to the allocated α=0.006 (two sided) for the final PFS analysis CI = confidence interval |
|||
Figure 3: Kaplan-Meier Curves for Overall Survival in ITT-WT Population in IMpower150
 |
Exploratory analyses showed that the subset of patients in the four drug regimen arm who were ADA positive by week 4 (30%) appeared to have similar efficacy (effect on overall survival) as compared to patients who tested negative for treatment-emergent ADA by week 4 (70%) [see CLINICAL PHARMACOLOGY]. In an exploratory analysis, propensity score matching was conducted to compare ADA positive patients in the intravenous atezolizumab, bevacizumab, paclitaxel, and carboplatin arm with a matched population in the bevacizumab, paclitaxel, and carboplatin arm. Similarly, ADA negative patients in the intravenous atezolizumab, bevacizumab, paclitaxel, and carboplatin arm were compared with a matched population in the bevacizumab, paclitaxel, and carboplatin arm. Propensity score matching factors were: baseline sum of longest tumor size (BSLD), baseline ECOG, baseline albumin, baseline LDH, sex, tobacco history, metastatic site, TC level, and IC level. The hazard ratio comparing the ADA-positive subgroup with its matched control was 0.69 (95% CI: 0.44, 1.07). The hazard ratio comparing the ADA-negative subgroup with its matched control was 0.64 (95% CI: 0.46, 0.90).
IMpower130
The efficacy of intravenous atezolizumab with paclitaxel protein-bound and carboplatin was evaluated in IMpower130 (NCT02367781), a multicenter, randomized (2:1), open-label trial in patients with stage IV non-squamous NSCLC. Patients with Stage IV non-squamous NSCLC who had received no prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor, if appropriate, were eligible. The trial excluded patients with history of autoimmune disease, administration of live attenuated vaccine within 28 days prior to randomization, administration of immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization, and active or untreated CNS metastases. Randomization was stratified by sex, presence of liver metastases, and PD-L1 tumor expression according to the VENTANA PD-L1 (SP142) assay as follows: TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1. Patients were randomized to one of the following treatment regimens:
Tumor assessments were conducted every 6 weeks for the first 48 weeks, then every 9 weeks thereafter. Major efficacy outcome measures were PFS by RECIST v1.1 and OS in the subpopulation of patients evaluated for and documented to have no EGFR or ALK genomic tumor aberrations (ITT-WT).
A total of 724 patients were enrolled; of these, 681 (94%) were in the ITT-WT population. The median age was 64 years (range: 18 to 86) and 59% were male. The majority of patients were White (90%), 2% of patients were Asian, 5% were Hispanic, and 4% were Black. Baseline ECOG performance status was 0 (41%) or 1 (58%). Most patients were current or previous smokers (90%). PD-L1 tumor expression was TC0/1/2 and IC0/1 in 73%; TC3 and any IC in 14%; and TC0/1/2 and IC2/3 in 13%.
Efficacy results for the ITT-WT population are presented in Table 26 and Figure 4.
Table 26: Efficacy Results from IMpower130
| Intravenous Atezolizumb with Paclitaxel Protein-Bound and Carboplatin | Paclitaxel Protein-Bound and Carboplatin | |
| Overall Survival1 | n = 453 | n = 228 |
| Deaths (%) | 228 (50%) | 131 (57%) |
| Median, months | 18.6 | 13.9 |
| (95% CI) | (15.7, 21.1) | (12.0, 18.7) |
| Hazard ratio2 (95% CI) | 0.80 (0.64, 0.99) | |
| p-value3 | 0.03844 | |
| Progression-Free Survival6 | n = 453 | n = 228 |
| Number of events (%) | 330 (73%) | 177 (78%) |
| Median, months | 7.2 | 6.5 |
| (95% CI) | (6.7, 8.3) | (5.6, 7.4) |
| Hazard ratio2 (95% CI) | 0.75 (0.63, 0.91) | |
| p-value3 | 0.00245 | |
| Overall Response Rate6,7 | n = 453 | n = 228 |
| Number of responders (%) | 207 (46%) | 74 (32%) |
| (95% CI) | (41, 50) | (26, 39) |
| Complete Response | 22 (5%) | 2 (1%) |
| Partial Response | 185 (41%) | 72 (32%) |
| Duration of Response6,7 | n = 207 | n = 74 |
| Median, months | 10.8 | 7.8 |
| (95% CI) | (9.0, 14.4) | (6.8, 10.9) |
| 1 Based on OS interim analysis 2 Stratified by sex and PD-L1 tumor expression on tumor cells (TC) and tumor infiltrating cells (IC) 3 Based on the stratified log-rank test 4 Compared to the allocated α=0.0428 (two sided) for this interim analysis 5 Compared to the allocated α=0.006 (two sided) for the final PFS analysis 6 As determined by independent review facility (IRF) per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1) 7 Confirmed response CI = confidence interval |
||
Figure 4: Kaplan-Meier Curves for Overall Survival in IMpower130
 |
OAK
The efficacy of intravenous atezolizumab was evaluated in a multicenter, international, randomized (1:1), open-label study (OAK; NCT02008227) conducted in patients with locally advanced or metastatic NSCLC whose disease progressed during or following a platinum-containing regimen. Patients with a history of autoimmune disease, symptomatic or corticosteroid-dependent brain metastases, or requiring systemic immunosuppression within 2 weeks prior to enrollment were ineligible. Randomization was stratified by PD-L1 expression tumor-infiltrating immune cells (IC), the number of prior chemotherapy regimens (1 vs. 2), and histology (squamous vs. non-squamous).
Patients were randomized to receive intravenous atezolizumab 1200 mg intravenously every 3 weeks until unacceptable toxicity, radiographic progression, or clinical progression or docetaxel 75 mg/m2 intravenously every 3 weeks until unacceptable toxicity or disease progression. Tumor assessments were conducted every 6 weeks for the first 36 weeks and every 9 weeks thereafter. Major efficacy outcome measure was overall survival (OS) in the first 850 randomized patients and OS in the subgroup of patients with PD-L1-expressing tumors (defined as ≥ 1% PD-L1 expression on tumor cells [TC] or immune cells [IC]). Additional efficacy outcome measures were OS in all randomized patients (n = 1225), OS in subgroups based on PD-L1 expression, overall response rate (ORR), and progression free survival as assessed by the investigator per RECIST v.1.1.
Among the first 850 randomized patients, the median age was 64 years (33 to 85 years) and 47% were ≥ 65 years old; 61% were male; 70% were White and 21% were Asian; 15% were current  smokers and 67% were former smokers; and 37% had baseline ECOG PS of 0 and 63% had a baseline ECOG PS of 1. Nearly all (94%) had metastatic disease, 74% had non-squamous histology, 75% had received only one prior platinum-based chemotherapy regimen, and 55% of patients had PD-L1-expressing tumors.
Efficacy results are presented in Table 27 and Figure 5
Table 27: Efficacy Results in OAK
| Intravenous Atezolizumab | Docetaxel | |
| Overall Survival in first 850 patients | ||
| Number of patients | N = 425 | N = 425 |
| Deaths (%) | 271 (64%) | 298 (70%) |
| Median, months | 13.8 | 9.6 |
| (95% CI) | (11.8, 15.7) | (8.6, 11.2) |
| Hazard ratio1 (95% CI) | 0.74 (0.63, 0.87) | |
| p-value2 | 0.00043 | |
| Progression-Free Survival | ||
| Number of Patients | N = 425 | N = 425 |
| Events (%) | 380 (89%) | 375 (88%) |
| Progression (%) | 332 (78%) | 290 (68%) |
| Deaths (%) | 48 (11%) | 85 (20%) |
| Median, months | 2.8 | 4.0 |
| (95% CI) | (2.6, 3.0) | (3.3, 4.2) |
| Hazard ratio1 (95% CI) | 0.95 (0.82, 1.10) | |
| Overall Response Rate4 | ||
| Number of Patients | N = 425 | N = 425 |
| ORR, n (%) | 58 (14%) | 57 (13%) |
| (95% CI) | (11%, 17%) | (10%, 17%) |
| Complete Response | 6 (1%) | 1 (0.2%) |
| Partial Response | 52 (12%) | 56 (13%) |
| Duration of Response3 | N = 58 | N = 57 |
| Median, months | 16.3 | 6.2 |
| (95% CI) | (10.0, NE) | (4.9, 7.6) |
| Overall Survival in all 1225 patients | ||
| Number of patients | N = 613 | N = 612 |
| Deaths (%) | 384 (63%) | 409 (67%) |
| Median, months (95% CI) | 13.3 (11.3, 14.9) | 9.8 (8.9, 11.3) |
| Hazard ratio1 (95% CI) | 0.79 (0.69, 0.91) | |
| p-value2 | 0.00135 | |
| 1 Stratified by PD-L1 expression in tumor infiltrating immune cells, the number of prior chemotherapy regimens, and histology 2 Based on the stratified log-rank test 3 Compared to the pre-specified allocated α of 0.03 for this analysis 4 Per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1) 5 Compared to the allocated α of 0.0177 for this interim analysis based on 86% information using O’Brien-Fleming boundary CI = confidence interval; NE = not estimable |
||
Figure 5: Kaplan-Meier Curves of Overall Survival in the First 850 Patients Randomized in OAK
 |
Tumor specimens were evaluated prospectively using the VENTANA PD-L1 (SP142) Assay at a central laboratory and the results were used to define the PD-L1 expression subgroups for pre-specified analyses. Of the 850 patients, 16% were classified as having high PD-L1 expression, defined as having PD-L1 expression on ≥ 50% of TC or ≥ 10% of IC. In an exploratory efficacy subgroup analysis of OS based on PD-L1 expression, the hazard ratio was 0.41 (95% CI: 0.27, 0.64) in the high PD-L1 expression subgroup and 0.82 (95% CI: 0.68, 0.98) in patients who did not have high PD-L1 expression.
Exploratory analyses showed that the subset of patients who were ADA positive by week 4 (21%) appeared to have less efficacy (effect on overall survival) as compared to patients who tested negative for treatment-emergent ADA by week 4 (79%) [see CLINICAL PHARMACOLOGY]. ADA positive patients by week 4 appeared to have similar OS compared to docetaxel-treated patients. In an exploratory analysis, propensity score matching was conducted to compare ADA positive patients in the atezolizumab arm with a matched population in the docetaxel arm and ADA negative patients in the atezolizumab arm with a matched population in the docetaxel arm. Propensity score matching factors were: baseline sum of longest tumor size (BSLD), baseline ECOG, histology (squamous vs. non-squamous), baseline albumin, baseline LDH, gender, tobacco history, metastases status (advanced or local), metastatic site, TC level, and IC level. The hazard ratio comparing the ADA positive subgroup with its matched control was 0.89 (95% CI: 0.61, 1.3). The hazard ratio comparing the ADA negative subgroup with its matched control was 0.68 (95% CI: 0.55, 0.83).
The efficacy of TECENTRIQ HYBREZA in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) has been established in adequate and well-controlled studies of intravenous atezolizumab in combination with carboplatin and etoposide for ES-SCLC. Below is a description of adverse reactions of intravenous atezolizumab in combination with carboplatin and etoposide in this adequate and well-controlled ES-SCLC trial.
IMpower133
The efficacy of intravenous atezolizumab with carboplatin and etoposide was investigated in IMpower133 (NCT02763579), a randomized (1:1), multicenter, double-blind, placebo-controlled trial in 403 patients with ES-SCLC. IMpower133 enrolled patients with ES-SCLC who had received no prior chemotherapy for extensive stage disease and ECOG performance status 0 or 1. The trial excluded patients with active or untreated CNS metastases, history of autoimmune disease, administration of a live, attenuated vaccine within 4 weeks prior to randomization, or administration of systemic immunosuppressive medications within 1 week prior to randomization. Randomization was stratified by sex, ECOG performance status, and presence of brain metastases. Patients were randomized to receive one of the following two treatment arms:
Administration of intravenous atezolizumab was permitted beyond RECIST-defined disease progression. Tumor assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Patients treated beyond disease progression had tumor assessment conducted every 6 weeks until treatment discontinuation.
Major efficacy outcome measures were OS and PFS as assessed by investigator per RECIST v1.1 in the intent-to-treat population. Additional efficacy outcome measures included ORR and DoR as assessed by investigator per RECIST v1.1.
A total of 403 patients were randomized, including 201 to the intravenous atezolizumab arm and 202 to the chemotherapy alone arm. The median age was 64 years (range: 26 to 90) and 65% were male. The majority of patients were White (80%); 17% were Asian, 4% were Hispanic and 1% were Black. Baseline ECOG performance status was 0 (35%) or 1 (65%); 9% of patients had a history of brain metastases, and 97% were current or previous smokers. Efficacy results are presented in Table 28 and Figure 6.
Table 28: Efficacy Results from IMpower133
| Intravenous Atezolizumab with Carboplatin and Etoposide | Placebo with Carboplatin and Etoposide | |
| Overall Survival | N = 201 | N = 202 |
| Deaths (%) | 104 (52%) | 134 (66%) |
| Median, months | 12.3 | 10.3 |
| (95% CI) | (10.8, 15.9) | (9.3, 11.3) |
| Hazard ratio3 (95% CI) | 0.70 (0.54, 0.91) | |
| p-value4,5 | 0.0069 | |
| Progression-Free Survival1,2 | N = 201 | N = 202 |
| Number of events (%) | 171 (85%) | 189 (94%) |
| Median, months | 5.2 | 4.3 |
| (95% CI) | (4.4, 5.6) | (4.2, 4.5) |
| Hazard ratio3 (95% CI) | 0.77 (0.62, 0.96) | |
| p-value4,6 | 0.0170 | |
| Objective Response Rate1,2,7 | N = 201 | N = 202 |
| Number of responders (%) | 121 (60%) | 130 (64%) |
| (95% CI) | (53, 67) | (57, 71) |
| Complete Response (%) | 5 (2%) | 2 (1%) |
| Partial Response (%) | 116 (58%) | 128 (63%) |
| Duration of Response1,2,7 | N = 121 | N = 130 |
| Median, months | 4.2 | 3.9 |
| (95% CI) | (4.1, 4.5) | (3.1, 4.2) |
| 1 As determined by investigator assessment 2 per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1) 3 Stratified by sex and ECOG performance status 4 Based on the stratified log-rank test 5 Compared to the allocated α of 0.0193 for this interim analysis based on 78% information using O’Brien-Fleming boundary 6 Compared to the allocated α of 0.05 for this analysis 7 Confirmed response CI = confidence interval |
||
Figure 6: Kaplan-Meier Plot of Overall Survival in IMpower133
 |
The efficacy of TECENTRIQ HYBREZA in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy has been established in adequate and well-controlled studies of intravenous atezolizumab in combination with bevacizumab for HCC. Below is a description of efficacy reactions of intravenous atezolizumab in combination with bevacizumab in this adequate and well-controlled HCC trial.
IMbrave150
The efficacy of intravenous atezolizumab in combination with bevacizumab was investigated in IMbrave150 (NCT03434379), a multicenter, international, open-label, randomized trial in patients with locally advanced unresectable and/or metastatic hepatocellular carcinoma who have not received prior systemic therapy. Randomization was stratified by geographic region (Asia excluding Japan vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), baseline AFP (< 400 vs. ≥ 400 ng/mL), and by ECOG performance status (0 vs. 1).
A total of 501 patients were randomized (2:1) to receive either intravenous atezolizumab as an intravenous infusion of 1200 mg, followed by 15 mg/kg bevacizumab, on the same day every 3 weeks or sorafenib 400 mg given orally twice daily, until disease progression or unacceptable toxicity. Patients could discontinue either intravenous atezolizumab or bevacizumab (e.g., due to adverse events) and continue on monotherapy until disease progression or unacceptable toxicity associated with the monotherapy.
The study enrolled patients who were ECOG performance score 0 or 1 and who had not received prior systemic treatment. Patients were required to be evaluated for the presence of varices within 6 months prior to treatment, and were excluded if they had variceal bleeding within 6 months prior to treatment, untreated or incompletely treated varices with bleeding, or high risk of bleeding. Patients with Child-Pugh B or C cirrhosis, moderate or severe ascites; history of hepatic encephalopathy; a history of autoimmune disease; administration of a live, attenuated vaccine within 4 weeks prior to randomization; administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization; or untreated or corticosteroid-dependent brain metastases were excluded. Tumor assessments were performed every 6 weeks for the first 54 weeks and every 9 weeks thereafter.
The demographics and baseline disease characteristics of the study population were balanced between the treatment arms. The median age was 65 years (range: 26 to 88) and 83% of patients were male. The majority of patients were Asian (57%) or White (35%); 40% were from Asia (excluding Japan). Approximately 75% of patients presented with macrovascular invasion and/or extrahepatic spread and 37% had a baseline AFP ≥ 400 ng/mL. Baseline ECOG performance status was 0 (62%) or 1 (38%). HCC risk factors were Hepatitis B in 48% of patients, Hepatitis C in 22%, and 31% of patients had non-viral liver disease. The majority of patients had BCLC stage C (82%) disease at baseline, while 16% had stage B, and 3% had stage A.
The major efficacy outcome measures were overall survival (OS) and independent review facility (IRF)-assessed progression free survival (PFS) per RECIST v1.1. Additional efficacy outcome measures were IRF-assessed overall response rate (ORR) per RECIST and mRECIST.
Efficacy results are presented in Table 29 and Figure 7.
Table 29: Efficacy Results from IMbrave150
| Intravenous Atezolizumab in combination with Bevacizumab (N= 336) |
Sorafenib (N=165) |
|
| Overall Survival | ||
| Number of deaths (%) | 96 (29) | 65 (39) |
| Median OS in months | NE | 13.2 |
| (95% CI) | (NE, NE) | (10.4, NE) |
| Hazard ratio1 (95% CI) | 0.58 (0.42, 0.79) | |
| p-value2 | 0.00062 | |
| Progression-Free Survival3 | ||
| Number of events (%) | 197 (59) | 109 (66) |
| Median PFS in months (95% CI) | 6.8 (5.8, 8.3) | 4.3 (4.0, 5.6) |
| Hazard ratio1 (95% CI) | 0.59 (0.47, 0.76) | |
| p-value | < 0.0001 | |
| Overall Response Rate3,5 (ORR), RECIST 1.1 | ||
| Number of responders (%) | 93 (28) | 19 (12) |
| (95% CI) | (23, 33) | (7,17) |
| p-value4 | < 0.0001 | |
| Complete responses, n (%) | 22 (7) | 0 |
| Partial responses, n (%) | 71 (21) | 19 (12) |
| Duration of Response3,5 (DOR) RECIST 1.1 | ||
| (n=93) | (n=19) | |
| Median DOR in months | NE | 6.3 |
| (95% CI) | (NE, NE) | (4.7, NE) |
| Range (months) | (1.3+, 13.4+) | (1.4+, 9.1+) |
| Overall Response Rate3,5 (ORR), HCC mRECIST | ||
| Number of responders (%) | 112 (33) | 21 (13) |
| (95% CI) | (28, 39) | (8, 19) |
| p-value4 | < 0.0001 | |
| Complete responses, n (%) | 37 (11) | 3 (1.8) |
| Partial responses, n (%) | 75 (22) | 18 (11) |
| Duration of Response3,5 (DOR) HCC mRECIST | ||
| (n=112) | (n=21) | |
| Median DOR in months | NE | 6.3 |
| (95% CI) | (NE, NE) | (4.9, NE) |
| Range (months) | (1.3+, 13.4+) | (1.4+, 9.1+) |
| 1 Stratified by geographic region (Asia excluding Japan vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (< 400 vs. ≥ 400 ng/mL) 2 Based on two-sided stratified log-rank test; as compared to significance level 0.004 (2-sided) based on 161/312=52% information using the OBF method 3 Per independent radiology review 4 Based on two-sided Cochran-Mantel-Haesnszel test 5 Confirmed responses + Denotes a censored value CI = confidence interval; HCC mRECIST = Modified RECIST Assessment for Hepatocellular Carcinoma; NE = not estimable; RECIST 1.1 = Response Evaluation Criteria in Solid Tumors v1.1 |
||
Figure 7: Kaplan-Meier Plot of Overall Survival in IMbrave150
 |
Exploratory analyses showed that the subset of patients (20%) who were ADA-positive by week 6 appeared to have reduced efficacy (effect on OS) as compared to patients (80%) who tested negative for treatment-emergent ADA by week 6 [see CLINICAL PHARMACOLOGY]. ADA-positive patients by week 6 appeared to have similar overall survival compared to sorafenib-treated patients. In an exploratory analysis, inverse probability weighting was conducted to compare ADA-positive patients and ADA-negative patients in the intravenous atezolizumab and bevacizumab arm to the sorafenib arm. Inverse probability weighting factors were: baseline sum of longest tumor size (BSLD), baseline ECOG, baseline albumin, baseline LDH, sex, age, race, geographic region, weight, neutrophil-to-lymphocyte ratio, AFP (< 400 ng/mL vs ≥ 400 ng/mL), number of metastatic sites, MVI and/or EHS present at study entry, etiology (HBV vs. HCV vs. non-viral) and Child-Pugh Score (A5 vs. A6). The OS hazard ratio comparing the ADA-positive subgroup of the intravenous atezolizumab and bevacizumab arm to sorafenib was 0.93 (95% CI: 0.57, 1.53). The OS hazard ratio comparing the ADA-negative subgroup to sorafenib was 0.39 (95% CI: 0.26, 0.60).
The efficacy of TECENTRIQ HYBREZA in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma has been established in adequate and well-controlled studies of intravenous atezolizumab in combination with bevacizumab for BRAF V600 mutation-positive unresectable or metastatic melanoma. Below is a description of the efficacy of intravenous atezolizumab in combination with cobimetinib and vemurafenib in this adequate and well-controlled melanoma trial.
IMspire150
The efficacy of intravenous atezolizumab in combination with cobimetinib and vemurafenib was evaluated in a double-blind, randomized (1:1), placebo-controlled, multicenter trial (IMspire150; NCT02908672) conducted in 514 patients. Randomization was stratified by geographic location (North America vs. Europe vs. Australia, New Zealand, and others) and baseline lactate dehydrogenase (LDH) [less than or equal to upper limit of normal (ULN) vs. greater than ULN].
Eligible patients were required to have previously untreated unresectable or metastatic BRAF V600 mutation-positive melanoma as detected by a locally available test and centrally confirmed with the FoundationOneTM assay. Patients were excluded if they had history of autoimmune disease; administration of a live, attenuated vaccine within 28 days prior to randomization; administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization; and active or untreated CNS metastases.
Intravenous atezolizumab was initiated after patients received a 28-day treatment cycle of cobimetinib 60 mg orally once daily (21 days on/7 days off) and vemurafenib 960 mg orally twice daily Days 1-21 and 720 mg orally twice daily Days 22-28. Patients received intravenous atezolizumab 840 mg intravenous infusion over 60 minutes every 2 weeks in combination with cobimetinib 60 mg orally once daily and vemurafenib 720 mg orally twice daily, or placebo in combination with cobimetinib 60 mg orally once daily and vemurafenib 960 mg orally twice daily. Treatment continued until disease progression or unacceptable toxicity. There was no crossover at the time of disease progression. Tumor assessments were performed every 8 weeks (± 1 week) for the first 24 months and every 12 weeks (± 1 week) thereafter.
The major efficacy outcome measure was investigator-assessed progression-free survival (PFS) per RECIST v1.1. Additional efficacy outcomes included PFS assessed by an independent central review, investigator-assessed ORR, OS, and DOR.
The median age of the study population was 54 years (range: 22–88), 58% of patients were male, 95% were White, a baseline ECOG performance status of 0 (77%) or 1 (23%), 33% had elevated LDH, 94% had metastatic disease, 60% were Stage IV (M1C), 56% had less than three metastatic sites at baseline, 3% had prior treatment for brain metastases, 30% had liver metastases at baseline, and 14% had received prior adjuvant systemic therapy. Based on central testing, 74% were identified as having a V600E mutation, 11% as having V600K mutation, and 1% as having V600D or V600R mutations.
Efficacy results are summarized in Table 30 and Figure 8. Patients had a median survival follow up time of 18.9 months.
Table 30: Efficacy Results from IMspire150
| Intravenous Atezolizumab + Cobimetinib + Vemurafenib N = 256 |
Placebo + Cobimetinib + Vemurafenib N = 258 |
|
| Progression-Free Survival1 | ||
| Number of events (%) | 148 (58) | 179 (69) |
| Median, months | 15.1 | 10.6 |
| (95% CI) | (11.4, 18.4) | (9.3, 12.7) |
| Hazard ratio2 (95% CI) | 0.78 (0.63, 0.97) | |
| p-value3 | 0.0249 | |
| Overall Response Rate1,4 | ||
| Number of responders (%) | 170 (66) | 168 (65) |
| (95% CI) | (60, 72) | (59, 71) |
| Complete responses, n (%) | 41 (16) | 46 (18) |
| Partial response, n (%) | 129 (50) | 122 (47) |
| Duration of Response1,4 | n = 170 | n = 168 |
| Median, months (95% CI) | 20.4 (15.1, NE) | 12.5 (10.7, 16.6) |
| 1 As determined by investigator assessment with Response Evaluation Criteria in Solid Tumors v1.1.; CI = confidence interval 2 Stratified by baseline LDH 3 Based on the stratified log-rank test 4 Confirmed responses |
||
Figure 8: Kaplan-Meier Plot for Progression-Free Survival in IMspire150
 |
At a pre-specified analysis at the time of the primary analysis of PFS, the OS data were not mature. The median OS was 28.8 months with 93 (36%) deaths in the intravenous atezolizumab plus cobimetinib and vemurafenib arm, and 25.1 months with 112 (43%) deaths in the placebo plus cobimetinib and vemurafenib arm. The hazard ratio for OS was 0.85 (95% CI: 0.64, 1.11) and the p-value was 0.2310.
The efficacy of TECENTRIQ HYBREZA as monotherapy for the treatment of adult patients with unresectable or metastatic alveolar soft part sarcoma (ASPS) has been established in adequate and well-controlled studies of intravenous atezolizumab for ASPS. TECENTRIQ HYBREZA is not indicated for the treatment of pediatric patients. Below is a description of the efficacy of intravenous atezolizumab in this adequate and well-controlled ASPS trial.
The efficacy of intravenous atezolizumab was evaluated in study ML39345 (NCT03141684), an open-label, single-arm study, in 49 adult and pediatric patients aged 2 years and older with unresectable or metastatic ASPS. Although this study enrolled pediatric patients, TECENTRIC HYBREZA is not indicated for use in pediatric patients. Eligible patients were required to have histologically or cytologically confirmed ASPS that was not curable by surgery, and an ECOG performance status of ≤ 2.
Patients were excluded if they had known primary central nervous system (CNS) malignancy or symptomatic CNS metastases, known clinically significant liver disease, or history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
Adult patients received 1200 mg intravenously and pediatric patients received 15 mg/kg (up to a maximum of 1200 mg) intravenously once every 21 days until disease progression or unacceptable toxicity.
The major efficacy outcomes were Overall Response Rate (ORR) and Duration of Response (DOR) by Independent Review Committee according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
A total of 49 patients were enrolled. The median age of patients was 31 years (range: 12–70); 2% of adult patients (n = 47) were ≥ 65 years of age and the pediatric patients (n = 2) were ≥ 12 years of age; 51% of patients were female, 55% White, 29% Black or African American, 10% Asian; 53% had an ECOG performance status of 0 and 45% had an ECOG performance status of 1. All patients had prior surgery for ASPS and 55% received at least one prior line of treatment for ASPS; 55% received radiotherapy and 53% received chemotherapy. Of the patients who reported staging at initial diagnosis, all were Stage IV.
Efficacy results of this study are summarized in Table 31.
Table 31: Efficacy Results from Study ML39345
| Endpoint | All Patients (N=49) |
| Overall Response Rate (95% CI)a | 24% (13, 39) |
| Complete responses, n | 0 |
| Partial responses, n (%) | 12 (24) |
| Duration of Response | |
| Median, month | NE |
| (95% CI) | (17.0, NE) |
| Range | 1+, 41+ |
| Durability of response | |
| ≥ 6 months, n (%) | 8 (67%) |
| ≥ 12 months, n (%) | 5 (42%) |
| CI:confidence interval; N: number of patients; +: Censored a 95% CI based on Clopper-Pearson exact method. |
|
The IMscin002 study (NCT03735121) was a randomized, multi-center, open-label cross-over trial conducted in 179 patients with either PD-L1-positive early-stage NSCLC receiving adjuvant treatment or were chemotherapy-naïve with high PD-L1 stage IV NSCLC. Patients were randomized (1:1) to receive 3 cycles of TECENTRIQ HYBREZA followed by 3 cycles of intravenous atezolizumab (Arm A) or 3 cycles of intravenous atezolizumab followed by 3 cycles of TECENTRIQ HYBREZA (Arm B).
Of the 126 eligible patients, 123 (98%) completed the patient preference questionnaire at the beginning of cycle 6 or after at least two consecutive cycles of each treatment method was administered in case of treatment discontinuation prior to cycle 6. Eighty-seven of 123 patients (71%) reported preferring subcutaneous administration of TECENTRIQ HYBREZA over intravenous atezolizumab and the most common reason was that administration required less time in the clinic; 26 out of 123 patients (21%) reported preferring intravenous atezolizumab over TECENTRIQ HYBREZA and the most common reason was that it felt more comfortable during administration; and 10 out of 123 patients (8%) had no preference for the route of administration.
Patients in both arms could continue to receive treatment after the crossover period for up to 16 cycles (patients with early-stage NSCLC) or until disease progression or unacceptable toxicity (patients with stage IV NSCLC). Of the 107 patients who reached the treatment continuation period, 85 (79%) patients (42 from IV/SC and 43 from SC/IV) chose to continue treatment with the SC route of administration.
TECENTRIQ HYBREZA™
(te-SEN-trik hye-BREEZE-uh)
(atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use
What is the most important information I should know about TECENTRIQ HYBREZA?
TECENTRIQ HYBREZA is a medicine that may treat certain cancers by working with your immune system. TECENTRIQ HYBREZA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.
Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:
Lung problems.
Intestinal problems.
Liver problems.
Hormone gland problems.
Kidney problems.
Skin problems.
Problems can also happen in other organs. These are not all of the signs and symptoms of immune system problems that can happen with TECENTRIQ HYBREZA. Call or see your healthcare provider right away for any new or worse signs or symptoms, including:
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:
Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death.
These complications may happen if you underwent transplantation either before or after being treated with TECENTRIQ HYBREZA. Your healthcare provider will monitor you for these complications.
Getting medical treatment right away may help keep these problems from becoming more serious.
Your healthcare provider will check you for these problems during your treatment with TECENTRIQ HYBREZA. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with TECENTRIQ HYBREZA if you have severe side effects.
What is TECENTRIQ HYBREZA?
TECENTRIQ HYBREZA is a prescription medicine used to treat adults with:
It is not known if TECENTRIQ HYBREZA is safe and effective in children.
Do not receive TECENTRIQ HYBREZA if you are allergic to hyaluronidase or any of the ingredients in TECENTRIQ HYBREZA. See the end of this Medication Guide for a complete list of ingredients in TECENTRIQ HYBREZA.
Before receiving TECENTRIQ HYBREZA, tell your healthcare provider about all of your medical conditions, including if you:
Females who are able to become pregnant:
How will I receive TECENTRIQ HYBREZA?
What are the possible side effects of TECENTRIQ HYBREZA?
TECENTRIQ HYBREZA can cause serious side effects, including:
The most common side effects of TECENTRIQ HYBREZA when used alone in NSCLC include:
The most common side effects observed with intravenous TECENTRIQ, which may be experienced with TECENTRIQ HYBREZA are shown below.
The most common side effects of TECENTRIQ when used alone as the first treatment for NSCLC include:
The most common side effects of TECENTRIQ when used alone in NSCLC that has spread or grown include:
The most common side effects of TECENTRIQ when used alone in ASPS include:
The most common side effects of TECENTRIQ when used in NSCLC with bevacizumab, paclitaxel, and carboplatin include:
The most common side effects of TECENTRIQ when used in non-squamous NSCLC with paclitaxel protein-bound and carboplatin include:
The most common side effects of TECENTRIQ when used in SCLC with carboplatin and etoposide include:
The most common side effects of TECENTRIQ when used in HCC with bevacizumab include:
The most common side effects of TECENTRIQ when used in melanoma with cobimetinib and vemurafenib include:
TECENTRIQ HYBREZA may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of TECENTRIQ HYBREZA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of TECENTRIQ HYBREZA.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about TECENTRIQ HYBREZA that is written for health professionals.
What are the ingredients in TECENTRIQ HYBREZA?
Active ingredients: atezolizumab and hyaluronidase-tqjs
Inactive ingredients: acetic acid, histidine, methionine, polysorbate 20, sucrose, water for injection.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
